Ctri Data Base India Icmr

Clinical trial registry database India/WHO
S. Trial UTRN.WHO CTRI No.and Status of

no No. Date TrialWHO
1 Trial 1 TEMP UTRN CTRI/2008/091 Completed

110920818- /000298, 27-05-
21122008400346 2009
2 Trial 2 TEMP UTRN CTRI/2010/091 Open to

084547349- /000016, 13-01- recruitment
070120101616999 2010

013618768- /000154, 12-06-
27082008248338 2009

033922579- /000066, 09-03- recruitment
12022009483602 2009

023324110- /000111, 13-05-
21032009531943 2009

095106093- /000022, 18-06- recruitment
15012009436721 2009
7 Trial 7 TEMP UTRN CTRI/2010/091 Closed to

065751749- /000020, 01-02- recruitment of
0701201016201816 2010 participants

085037996- /000028, 15-01-
09012010162852 2010

110121271- /000029, 23-04- recruitment of
09012010162952 2010 participants
115252025- /000031, 23-04- recruitment of
09012010163152 2010 participants

080354168- /001071, 11-05- recruitment
231220091572599 2010

122452186- /000204, 11-02- recruitment
10102008301599 2009

035051948- /000182, 13-05- recruitment
16042009602241 2009

053105122- /000183, 13-05- recruitment
16042009603241 2009

061806049- /000184, 13-05- recruitment
16042009604241 2009

033519060- /000279, 27-05- recruitment
150520097221180 2009

111634368- /000401, 30-04- recruitment
1904201020223272 2010

105647370- /000043, 28-04- recruitment
2112200757179 2008
19 Trial 19 TEMP UTRN CTRI/2008/091 Not yet

111501559- /000047, 30-04- recruiting
22042008122327 2008

060332551- /000025, 09-07- recruitment
0801201016251569 2010
060355560- /000026, 10-03- recruitment
0801201016261569 2010
22 Trial 22 TEMP UTRN CTRI/2010/091 Not yet

033138488- /001098, 13-07- recruiting
100720102402235 2010
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
y database India/WHO
Last Verified Last Updated Speciality-

on on Subspeciality
5/27/2009 4/8/2010 Congestive heart

failure
1/13/2010 3/26/2010
acute renal failure

6/12/2009 12/23/2009 Chronic
Obstructive
Pulmonary Disease
3/9/2009 4/23/2009 Chronic

Obstructive
Pulmonary Disease
5/13/2009 3/18/2010 Chronic

Obstructive
Pulmonary Disease
6/18/2009 6/24/2010 Septic Shock
2/1/2010 2/1/2010 H1N1
1/15/2010 4/19/2010 H1N1
1/1/2007 5/13/2010 H1N1

4/23/2010 5/13/2010 H1N1
5/11/2010 5/5/2010 Shock
2/11/2009 2/11/2009 cardiac

arrhythmias
5/13/2009 5/15/2009 Pulmonary Arterial

Hypertension

Hypertension

Hypertension

Hypertension

Hypertension
4/28/2008 5/20/2010 life-threatening

illness

illness

illness
illness

illness
Public Title StudyWHO* Scientific Title of StudyWHO* T.
sample
size
Cardiac rehabilitation and quality The effects of exercise based cardiac 28

of life in congestive heart failure rehabilitation on quality of life in
congestive heart failure
A clinical trial to study the effects A Phase III, Multicenter, Open-Label 31

of a drug, Gammaplex, in patients Study To Evaluate the Efficacy and
with chronic Idiopathic Safety of GAMMAPLEX® in
Thrombocytopenic Purpura Chronic Idiopathic
Study to assess efficacy & safety AThrombocytopenic
open-labelled, prospective,
Purpura
of doxofylline 400 mg twice daily randomized, two-arm, parallel group
versus doxofylline 800 mg ER 4-week clinical study to assess
once daily in the treatment of efficacy & safety of doxophylline
Efficacy
chronicand Safety ofpulmonary
obstructive Indacaterol Aextended
Phase III,release
26-Week 800Multi-Center
mg OD vs
in Adults (40 Years and Above)
disease. Randomized
doxophylline Double-Blind,
400 mg BD Placebo-
in the
With Chronic Obstructive Controlled,
treatment of Parallel-Group Study to
patients with chronic
Pulmonary Disease (COPD) Assess the Efficacy, Safety
obstructive pulmonary disease. and
A clinical trial to study the effects An open of
Tolerability label, comparative,
Indacaterol (150 and 200
of two drugs, fixed dose 300multicentric study toWith
µg o.d.) in Patients assessChronic
the
combination of Formoterol efficacy
Obstructiveand Pulmonary
safety of fixed-dose
Disease
fumarate & Mometasone furoate combination of Formoterol
(COPD) fumarate
Efficacy
dry powder and Safety
inhaler of dose
and fixed A Randomized,
& Mometasone Double-blind,
furoate Dry Powder 1696
Drotrecogin
combination Alfaof (Activated)
Formoterol in Placebo-controlled, Multicenter,
Inhaler (DPI) and fixed-dose
Adult Patients
fumarate & with Septic Shock
Budesonide dry Phase 3 Study
combination of of Drotrecogin
Formoterol Alfa
fumarate
powder inhaler in patients with (Activated) Administered
& Budesonide Dry Powder Inhaler as a
Study
bronchialof Swine-Origin
asthma and/orA/H1N1
chronic Bridging
Continuous
(DPI) Study
for the96-hr on Safety
Infusion
treatment toand
Adult
of bronchial 100
Influenza Non-Adjuvanted
obstructive pulmonary disease Immunogenicity
Patients
asthmaWith of an
Septic
and/or Intramuscular
Shock
chronic Acronym:
obstructive
Vaccine in(COPD).
Healthy Adults in Inactivated, Split
PROWESS-SHOCK
pulmonary Virion
disease Swine-
(COPD).
India Origin A/H1N1 Influenza Non-
A clinical study to Evaluate The A Randomized,
Adjuvanted Double
Vaccine Blind,
in Healthy 72
Safety, Tolerability And Comparative,
AdultsPhase I Study To
in India
Immunogenicity Of Three Evaluate The Safety, Tolerability And
Formulations (15µg Without Immunogenicity Of Three
A Phase II/III
Adjuvant, 7.5µgclinical Study to
With Adjuvant AFormulations
Randomized,(15µg Double Blind,
Without 360
Evaluate
And 3.75µg the Immunogenicity
With Adjuvant) Of and Comparative,
Adjuvant, 7.5µgPhase
WithII/III StudyAnd
Adjuvant to
Safety of Three
Monovalent Formulations
H1N1 Influenza Aof Evaluate
3.75µg theWith
Immunogenicity
Adjuvant) Ofand
Monovalent H1N1 Influenza
(2009) Virus Vaccine In Healthy A Safety
Monovalent H1N1 Influenza [15
of Three Formulations A
(2009) Adults.
Virus Vaccine, mcg (unadjuvanted), 7.5
(2009) Virus Vaccine In Healthy mcg
Manufactured by Panacea Biotec (adjuvanted) and 3.75 mcgg
Adults.
Ltd., in Healthy Pediatric (adjuvanted)] of Monovalent H1N1
Population 6 - 35 Months of Age. Influenza A (2009) Virus Vaccine,
Manufactured by Panacea Biotec
Ltd., in Healthy Pediatric Population
6 - 35 Months of Age.
A Phase II/III clinical Study to A Randomized, Double Blind, 360
Evaluate the Immunogenicity and Comparative, Phase II/III Study to
Safety of Three Formulations of Evaluate the Immunogenicity and
Monovalent H1N1 Influenza A Safety of Three Formulations [15
Medtronic-
(2009) Shock-Less
Virus Vaccine, study to Shock-Less study: A prospective,
mcg (unadjuvanted), 7.5 mcg 3000
determine whether
Manufactured by Panaceaperiodic
Biotec non-randomized,
(adjuvanted) and multi-centre
3.75 mcgpost
reports
Ltd.,delivered
in Healthy to study centers
Pediatric marketofclinical
(adjuvanted)] trial. H1N1
Monovalent
can increase use of
Population 3-9 years of Age.shock Influenza A (2009) Virus Vaccine,
PANARMreductionHF programming.
: A clinical registry PANARM
Manufactured HF -Abyprospective, multi- 2000
Panacea Biotec
to understand the disease profiles center,
Ltd., non-interventional
in Healthy to collect
Pediatric Population
of patients who suffer from (at the referring physician
3 - 9 Years of Age.stage), data
cardiac arrhythmias and/or heart pertaining to the demographic,
SR-PAAS
failure and - Sitaxentan
to understand Efficacy
the A Phase 3,and
cardiovascular Multi-Center,
disease etiology
and Safety
diagnosis Trial With
and treatment a
pathway Randomized,
profiles ofDouble-Blind,
patients who havePlacebo-
Randomized Prospective
of these patients Controlled, Safety
symptomatic cardiacAnd Efficacy
arrhythmias
Assessment of Adding Sildenafil &/or left ventricular dysfunction In
Study Of Sitaxsentan Sodium with
Open-Label Study Providing A Phase
Subjects 3, Multi-Center,
With Pulmonary Open Label
Arterial
or without symptoms of heart failure. 180
Monotherapy (Sitaxsentan) and Study To Evaluate The Long-Term
Hypertension.
Combination Therapy Safety Of Monotherapy Sitaxsentan
(Sitaxsentan+Sildenafil) to Sodium And Combination Therapy
Study Looking
Subjects With PAHat Combination
to Assess WithA Phase 3, Multi-Center,
Sitaxsentan Sodium And 180
Therapy (Sitaxsentan+Sildenafil)
Long-Term Safety. Randomized, Double-Blind,
Sildenafil Citrate In SubjectsEfficacy
With
vs. Monotherapy (Sitaxsentan And Safety Arterial
Pulmonary Study OfHypertension.
Monotherapy
Alone) SR-PAAS -Sitaxentan Sitaxsentan Sodium Versus
A Research
Efficacy andStudy
Safety ToTrial
Assess
WithThea A Phase 2a, Randomized,
Combination Therapy WithDouble 72
Effectiveness
RandomizedAnd Safety Of
Prospective Blind, Placebo-Controlled,
Sitaxsentan Parallel
Sodium And Sildenafil
Different Doses
Assessment of AddingOf Oral PF-
Sildenafil Group
CitrateStudy Investigating
In Subjects The Dose-
With Pulmonary
00489791 In The Treatment Of Response Of PF-00489791
Arterial Hypertension Who OnHave
Acute
An open
Adult labelWith
Patients clinical trial to
Pulmonary Long term single-arm
Hemodynamics
Completed open label
In Subjects
Study B1321001. With Approx
study the effects
Arterial of long term
Hypertension. extension study
Idiopathic of the SERAPHIN
And Familial Pulmonary 699
administration of study drug to study to assessHypertension.
ARTERIAL the safety and
Improve Clinical Outcome in tolerability of ACT-064992 in
A study to Arterial
Pulmonary determine the safety
Hypertension A Phase
patients with2,symptomatic
Placebo-Controlled,
pulmonary 200
and activity
patients who of a novel oral
participated agent,
earlier in Randomized, Discontinuation
arterial hypertension AcronymTrial of
AV-951, theinSeraphin
patientsstudy
with kidney AV-951
SERAPHIN in Patients
(OL)-With
StudyRenal
with Cell
an
cancer To determine the safety Carcinoma
ERA in Pulmonary arterial
Aandclinical trialof
efficacy to AV-951
study theforeffects
the A Proof
Hypertensionof Concept prospective,
to Improve cliNical 180
of 2 Ayurvedic
treatment formulations,
in patients with Renal double-blind,
outcome placebo controlled,
(Open Label)
containing Ashwagandha,
cell carcinoma. Brahmi comparative, randomized, parallel
and Amalaki on the physical and group, multi-centric clinical study to
An Extension
emotional Treatment
well-being of Protocol
elderly An Extension
evaluate Treatment
short-term Protocol
effect of PHP- for 500
for Subjects who have
subjects. Subjects
Ageing onwho have Participated
the physical in a
and emotional
Participated in AV-951-09-301 Phase 3 Study
well-being of Tivozanib
of elderly vs.
subjects.
study Sorafenib in Renal Cell Carcinoma
(Protocol AV-951-09-301)
A Clinical Trial Study to Compare A Phase 3, Randomized, Controlled, 500
Tivozanib to Sorafenib in Subjects Multi-Center, Open-Label Study to
With advanced Renal Cell Compare Tivozanib (AV-951) to
Carcinoma Sorafenib in Subjects With Advanced
A clinical trial to study the effects Phase III randomized
Renal trial of BIBW
Cell Carcinoma 900
of a new drug and compare the 2992 plus weekly paclitaxel versus
effect of BIBW 2992 along with Investigator?s choice of
paclitaxel and investgators choice chemotherapy following BIBW 2992
chemotherapy in patients with monotherapy in non-small cell lung
Non-Small Cell Lung Cancer cancer patients failing previous
failing previous erlotinib or erlotinib or gefitinib treatment
gefitinib treatment
Phase Esti trial total Sites Site 1 Site 2 Site 3 Site 4
duration no
Not 1 Years 1 Department

Applicable of
physiotherap
y
Phase 3 2 Years 10
Phase 4 Months 1 Government

Medical
College &
Hospital
Phase 3 Months 2 HEALTH SDS
AND Tuberc
RESEARCH ulosis
CENTRE and
Phase 3 5 Chest & TB Mahatm
Rajiv ASHR Indore
Hospital aGandhi AI Chest
Gandhi
Institute ASSOC Centre,
Nationa
of IATES, Indore
Phase 3 4 Years 15 Grant Deenan
lChest KEM Ahmed Dept. of
Medical ath
Disease Hospita
Institute abad Pulmon
Foundation, Manges
of l& ary and
Ruby Hall hkar
Medical Researc Critical
Phase 3 12 Months 3 Post Graduate
Clinic, 40 Depart
Science Profess
Hospita h Care
Institute
Sassoon of ment of or
ls,&Jaipur and
Centre, Medicin
Medical
Road, Pune- Pediatri
Researc Head,
Depart e,
Education
411 001, cs
h Pediatri
ment of Apollo
Phase 1 85 Days 1 Fortis
and Research
Maharashtra Centre. cCardiol
centre Hospita
Clinical ogy, ls,
Research Ltd 489- 154/11,
Rasta Opp.
Phase 95 Days 7 ICH (Institute GR G.S.V.
Peth, Dr.D.Y.
IIM,
2/Phase 3 of Child Medical M Sardar Patil
Banner
Health) College College
Moodli Medical
ghatta
ar Road College
Road
Phase 95 Days 7 M.G.M GR Dr. G.S.V.
2/Phase 3 Medical Medical Ritabrat M
College and College a College
Chacha Kundu
Phase 4 4 Years 6 Max
NehruDevki Max Sri Escorts
Devi Heart &
Chikatsalya Balaji Chitra Heart
Vascular Hospita Insitute Institute
Institute l for &
Not 2 Years 8 C-4/3 Vasant Escort Heart
Medical Fortis
research
Applicable Vihar Heart & Care
sciences Escorts
center
Researc Clinic
& Hospita
h technol l
Phase 3 Months 5 Meenakshi The
Institute Poona
ogy Heart
Mission Heart Hospita First
Hospital and Care l& Cardiac
Research Clinic Researc And
Phase 3 58 Months 5 Kovai
Centre Meenak The h Poona
Vascula
Medical shi Heart
Centre Hospita
r Centre
Center and Mission Care l&
Hospital Hospita Clinic Researc
Phase 3 27 Months 5 Kovai
Limited Meenak
l and The Poona
h
Medical shi
Researc Heart HospitaCentre
Center and Mission
h Care l&
Hospital Hospita
Centre Clinic Researc
Phase 2 8 Months 3 Bankers
Limited Depart
l and Depart h
Heart ment
ResearcOf ment Of Centre
Institute Cardiol
h Cardiol
ogy,
Centre ogy,
Sri
Phase 3 4.5 Years 6 KEM G. B. P.D
Venkate MediCit Deenan
Hospital & Pant
swara Hinduja
i ath
Seth G.S. Hospita
Institute Nationa
Hospita Manges
Medical lOf ll, hkar
Phase 2 2 Years 5 Jaslok
College Rajiv
Medical Christia
Hospita Dept.
Hospitaof
Hospital & Gandhi
Science n l& Oncolo
l
Research Cancer
s Medical gy, Tata
Centre Institute College
Researc Memori
Phase 2 12 Months 4 TNMC & Seth
& Deccan
,h Vydehi
al
BYL Nair G.S.
Researc College
Centre Institute
Depart Hospita
Hospital, Medical
h of
ment of of
l
Mumbai College
Centre oncolog Medical
Medical
Phase 3 2 Years 12 Rajiv Gandhi
Central, Searoc
& KEM Shyam Science
y Mehdi
Science
Cancer
Mumbai 400 Cancer
Hospita Hemato
s& Nawaz
and
Institute
008 and Centre,
l, Parel, logy-
Allied Jung
Researc
Research Mumba hospital insitute,
Oncolo h
Centre, i 400 gy
s,Kanch Centre,
012 Clinic
anbhag 82,
Santosh EPIP
nagar,H area,
yderaba Whitefi
d- eld.
Phase 3 2 Years 12 Rajiv Gandhi Searoc Shyam Mehdi
Cancer Cancer Hemato Nawaz
Institute and Centre, logy- Jung
Research Oncolo insitute,
Phase 3 2 Years 5 Grant
Centre, Tata Dr.
gy Bhagwa
Medical Memori Kamaks
Clinic n
Foundation al hi Mahave
Hospita Memori er
l al Cancer
Hospita Hospita
l l and
Researc
h
Centre
Site 5 Site 6 Site 7 Site 8 Site 9 Site 10
L.T.M. L.T.M.
Medical Medical
College College
& &
Naraya
L.T.M. Escorts
Indrapr Apollo Dept. of Medicit
L.T.M.
na
G.H. Heart
G.H.ashtha Hospita Anaesth i
Hruday Institute
Apollo ls esiolog Hospita
alaya & Hospita y, l, 5-9-
Institute Researc
l K.L.E. 22,
of h Prabaka Near
Medical Centre r Kore Sarovar
Science Hospita Hotel,
s, l and Secretar
M.R.C, iat
PMO Road
466,
M.G.M Sant K.C Shivaba
Medical Dnyane General savanag
College shwar Hospita ar,
and Medical l
Chacha Educati
Nehru on
Chikats Researc
alya h
Centre
Dr.D.Y. Sant K.C
Patil Dnyane General
Medical shwar Hospita
College Medical l
Medant Postgra
Educati
a Heart duate
on
Institute Institute
Researc
, of
h
Fortis
Medant Escorts
Medical
Centre Escorts Indrapr
Hospita
a - The Hospita
Educati Hospita astha
l,
Medicit lon&& l Apollo
Mohali
y Researc Hosp
Kovai h
Medical Center
Center
and
Heart
Hospita
First
l
Cardiac
Limited
And
Heart
Vascula
First
r Centre
Cardiac
And
Vascula
r Centre
Care Apollo
Hospita Hospita
l l
Internat
Orchid ional
Nursing Limited
Home ,
Christia Orchid Shatabd Deenant Chatrap Oyster Mahavi S.M.S

n Nursing i h ati and r Medical
Medical home Supersp Manges Shahuji Pearl Cancer College
College eciality hkar Maharaj hospital Sanstha &
and Hospita Hospita Medical n attached
Hospita l, l& Univers Hospita
l, Researc ity l
h
Center
Christia Orchid Shatabd Deenant Chatrap Oyster Mahavi S.M.S
n Nursing i h ati and r Medical
Medical home Supersp Manges Shahuji Pearl Cancer College
College eciality hkar Maharaj hospital Sanstha &
Kota
and Hospita Hospita Medical n attached
Cancer
Hospita l, l& Univers Hospita
Hospita
l, Researc ity l
l and h
Researc Center
h
Centre
S. Trial UTRN.WHO CTRI Status Last Last

no No. No.and of Verified on Updated on
Date TrialWH
O
1 Trial 1 TEMP UTRN CTRI/2 Complet 2/6/2009 2/4/2009
112432317- 008/09 ed
15112008348703 1/0002
50, 06-
02-
2 Trial 2 TEMP UTRN CTRI/2
2009 Complet 9/24/2009 7/27/2009
071031378- 009/09 ed
13022009485959 1/0000
68, 24-
09-
2009 Open to 1/13/2010 5/25/2010
030230946- 010/09 recruit
0601201016142252 1/0000 ment
14, 13-
01-
2010
4 Trial 4 TEMP UTRN CTRI/2 Not yet 6/28/2010 6/24/2010
012958774- 010/09 recruiti
2601201016942821 1/0000 ng
90, 28-
06-
2010 Open to 6/25/2010 5/19/2010
061437776- 010/09 recruit
1703201018803114 1/0002 ment
64, 25-
06-
2010 Open to 5/20/2010 5/18/2010
034608176- 010/09 recruit
0903201018463090 1/0002 ment
31, 20-
05-
2010 Not yet 5/24/2010 5/24/2010
011854564- 010/09 recruiti
1404201020043393 1/0003 ng
83, 24-
05-
2010 Open to 6/28/2010 7/20/2010
124004469- 010/09 recruit
2304201020391247 1/0004 ment
17, 28-
06-
9 Trial 9 2010
10 Trial 10
11 Trial 11
12 Trial 12
13 Trial 13
14 Trial 14
15 Trial 15
16 Trial 16
17 Trial 17
18 Trial 18
19 Trial 19
20 Trial 20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
Speciality- Public Title StudyWHO* Scientific Title of T. Phase
Subspecialit StudyWHO* sample
y size
Nephro OPTIMIZATION OF PLASMA LEVEL MONITORING 25 Phase 4

MYCOPHENOLIC ACID OF MYCOPHENOLIC ACID IN
TREATMENT IN RENAL RENAL TRANSPLANT
TRANSPLANT RECIPIENTS RECIPIENTS
Nephro "The effectiveness of a "The effectiveness of a 86 Phase

behavioral change behavioral change 2/Phase
communication model in communication model in 3
promoting physical activity promoting physical activity
among females with typeII among females with typeII
Nephro Effects
Diabetesof mellitus"
strength training in Impact
Diabetesofmellitus"
short term 50 Phase 2
patients undergoing dialysis structured Progressive
on biochemical parameters, Resistance Training (PRT) in
functional capacity and intradialytic patients (DiaPRE
quality of life. study) in the improvement of
small solute clearance,
Nephro A clinical trial to study the Effect of N-Acetylcysteine on 100 Not
functional capacity, Health
effect of n-acetylcysteine on Oxidative Stress, Endothelial Applicabl
related quality of life (HQRL),
endothelial Dysfunction and Carotid e
dysfunction,oxidative stress and anthropometric
Artery Intimal Thickness measures
in
? double blind randomized
and carotid artery intimal Chronic Peritoneal Dialysis
Nephro To study the
thickness in chronic dialysis parallel
effect of Patientsgroup
Tacrolimus active
-AnasOpen
induction
Labeled 20 Not
tacrolimus
patients. in patients with controlled
therapy trial
for proliferative
Randomized Trial lupus Applicabl
lupus nephritis nephritis e
Nephro Comparison of efficacy of Comparison of efficacy of 50 Not

Tacrolimus versus Tacrolimus versus Applicabl
Cyclophosphamide in Cyclophosphamide in e
Idiopathic Membranous Idiopathic Membranous
Nephropathy Nephropathy
Nephro A clinical trial to compare Comparison of egg protein vs. 50 Phase 4
two protein supplements, whey protein supplements in
egg protein and whey dialysis patients.
protein in dialysis patients.
Nephro Research Study to A Phase III, Randomized, 350 Phase 3

demonstrate that Comparative, Open-label
intravenous iron Study of Intravenous Iron
isomaltoside 1000 Isomaltoside 1000
(Monofer®) is non-inferior to (Monofer®) administered by
oral iron sulphate in reducing Infusions or Repeated Bolus
renal related anemia in Injections in Comparison with
subjects with non-dialysis oral iron sulphate in Subjects
dependent chronic kidney with Non-Dialysis Dependent
disease (NDD-CKD), Chronic Kidney Disease and
determined as ability to with Renal-Related Anaemia.
increase Hb.
Esti total Sites Site 1 Site 2 Site 3 Site 4 Site 5 Site 6 Site 7
trial no
durati
on
1.5 Year 1 Departme
s nt of
Pharmaco
logy and
Nephrolog
y
Diabetic
4 Months 1
clinic
OP,Thiruv
ananthap
uram
3 Years 1 medical
Dialysis
college
Unit,
Central
Referral
Hospital
12 Mont 1 Dept. of
hs nephrolog
y
6 1 AIIMS
Months
1 Years 1 AIIMS
6 Months 1 Aditya
Birla
Memorial
Hospital
17 Mont 10 Pushpaw S.K. Soni MAMC Deenanat P. D. Apex Krishna

hs ati Hospital College, h Hinduja Kidney Institute of
Singhania Lok Mangeshk National Care Pvt Medical
Research Nayak ar Hospital Ltd, Sciences
Institute Hospital Hospital & and
Research Research
Centre Center
Site 8 Site 9 Site T. Phase Esti
10 sample trial
size durati
on
Departme Muljibhai Departme

nt of Patel nt of
Nephrolog Urological Nephrolog
y,Osmani Hospital, y,SMS
a General Dr. Medical
Hospital Virendra College
Desai and
Road, Hospital,
Nadiad, Jawahar
Gujarat Lal Nehru
Marg
,Jaipur-
302004,
India
S. no Trial No. UTRN.WHO CTRI No.and Date Status of TrialWHO
1 Trial 1 TEMP UTRN CTRI/2007/091/0000 Closed to

034131515- 13, 23-11-2007 recruitment follow
030920071653 up continuing &
closed to recruitment
follow up complete
2 Trial 2 TEMP UTRN CTRI/2009/091/0005 Open to recruitment
fully
045105887- 66, 14-09-2009
1607200910291247

024422692- 16, 16-09-2008
030220088248

011412431- 28, 11-04-2008
1303200898187

083206140- 29, 30-05-2008 recruitment of
1503200899280 participants
6 Trial 6 TEMP UTRN CTRI/2008/091/0000 Completed

100645310- 43, 23-04-2008
16042008118313

042145762- 45, 30-04-2008 recruitment of

025944501- 56, 13-05-2008
30042008131146

110711022- 17, 18-08-2008
23072008211450
020611453- 28, 21-08-2008 recruitment of

121809974- 59, 30-04-2009
02092008253191

103823171- 36, 07-01-2009
06112008333191

083356504- 77, 17-12-2008
10122008377187

104712413- 16, 16-01-2009 recruitment of

041121912- 27, 06-03-2009
15012009441872

105000976- 32, 31-07-2009
19012009446292

010112594- 57, 11-02-2009
0902200947465

053546631- 73, 01-04-2009
19022009490146
19 Trial 19 TEMP UTRN CTRI/2009/091/0001 Not yet recruiting

084701251- 15, 27-03-2009
24032009535191
043820600- 49, 02-04-2009
310320095691134

032053841- 81, 22-05-2009
1604200960153
22 Trial 22 TEMP UTRN CTRI/2009/091/0002 Terminated

031727816- 07, 05-05-2009
240420096271032

044909658- 04, 21-08-2009
230420096241220

022805993- 95, 21-08-2009
20052009739179

095709609- 83, 06-11-2009
18052009726422

115924240- 19, 18-05-2009
290420096391230

115410081- 54, 07-10-2009 recruitment of

062441378- 62, 08-06-2009 recruitment of

041905807- 93, 03-09-2009 recruitment of
110258934- 93, 31-03-2010
20052009737872

115603120- 78, 23-09-2009
300620099401266
32 Trial 32 TEMP UTRN CTRI/2009/091/0003 Terminated

023023778- 62, 25-06-2009
120620098121510

023242988- 82, 09-07-2009
170620098321569

114134924- 24, 06-08-2009
230620098811534

104816397- 77, 23-09-2009 recruitment of

013216120- 41, 04-08-2009 recruitment of

104806323- 95, 15-10-2009 recruitment of

034931413- 16, 07-12-2009
060720099791266

093307396- 21, 06-11-2009
07072009984146
025654840- 59, 14-09-2009
150720091022146

100055778- 42, 18-11-2009
2307200910471854

110112544- 37, 31-08-2009
1108200911031386

111132892- 81, 12-07-2010
1404201020021247

122022538- 94, 25-09-2009
3108200911632037

104256160- 71, 28-10-2009
160920091245191

113223348- 90, 30-09-2009
2309200912671444

042216998- 95, 22-01-2010
23092009127236

032333861- 00, 14-10-2009
2509200912781134

041442161- 17, 14-10-2009 recruitment of
105619330- 57, 20-10-2009
1410200913411134

021250245- 75, 06-11-2009 recruitment of

125126374- 90, 23-04-2010
301020091377872

054232650- 00, 19-11-2009
0211200913881220

110004254- 24, 19-03-2010
081220091524187

043107269- 15, 17-02-2010
060120101615461

025907064- 42, 15-12-2009
111220091543129

101233806- 60, 23-12-2009
1612200915611134

111135404- 36, 22-02-2010
0902201017471386

030939207- 77, 09-03-2010
220220101790146
112053446- 90, 13-04-2010
250220101803146

041841416- 77, 31-03-2010
1903201018941134

023347243- 33, 26-05-2010
2704201020563461

023429554- 41, 17-05-2010
2804201020653458

031230504- 10, 29-06-2010
0806201022371386

015212606- 52, 12-07-2010
2806201023542133
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
Last Verified Last Updated Speciality- Public Title StudyWHO*
on on Subspeciality
11/9/2008 17-04-2009 Onco .A clinical trial to study the
effects, (side effects and
efficacy) of two combinations of
chemotherapy drugs,
(Paclitaxel, ifosfamide and
14-02-2009 1/9/2009 Onco Treatment of patients with
Cisplatin) with (Paclitaxel,
Aggressive Lymphoma
cisplatin and 5-FU) in patients
following Self Stem Cell
with Locally Advanced Head
Transplantation
and Neck Cancer
16-09-2008 30-12-2008 Onco Phase III Randomized Trial of
Maintenance Pegylated
Liposomal Doxorubicin (PLD) /
Carboplatin versus without in
Patients with Advanced
11/4/2008 1/7/2008 Onco A double blind clinical trial
Ovarian Cancer
comparing the study drug and
placebo as second line therapy
for treatment of Locally
Advanced or Metastatic Non
30-05-2008 23-10-2008 Onco A study to assess the effect of
Small Cell Lung Cancer
two chemotherapy drugs
(NSCLC)?.
(paclitaxel and Cisplatin) along
with radiation in treating
cancer of the uterine cervix
23-04-2008 1/1/2007 Onco Effect of Praneem polyherbal
formulations against Infection
of HPV in Uterine cervix.
30-04-2008 23-02-2009 Onco To compare two advanced high-

precision radiotherapy
techniques in head and neck
cancers.
13-05-2008 24-02-2009 Onco Effect of no head shaving in
Neurosurgery on the risk of
wound infection
18-08-2008 18-07-2009 Onco A clinical trial to study the

efficacy of probiotic
Lactobacillus brevis lozenges in
preventing radiation and
chemotherapy induced oral
mucositis in head and neck
cancer patients.
21-08-2008 10/6/2010 Onco Study of Bavituximab plus
Paclitaxel and Carboplatin in
patients with Non small Cell
Lung Cancer.
22-09-2008 30-04-2009 Onco A phase II clinical trial to study
the efficacy and safety of a new
drug P276-00 in treatment of
recurrent and/or advanced
head and neck cancer
7/1/2009 1/10/2009 Onco A Phase I Study Of Selective
Cyclin Dependent Kinase
Inhibitor P1446A-05 In
Subjects With Advanced
Refractory Malignancies
17-12-2008 11/12/2008 Onco A Multinational Randomized
Double Blind, Placebo-
controlled study to evaluate the
efficacy and safety of AVE5026
in the prevention of Venous
16-01-2009 3/7/2009 Onco A clinical trial to study the
Thromembolism(VTE) in
safety and efficacy of ALD518
cancer patients at high risk for
in patients with non-small cell
VTE and who are undergoing
lung cancer-related fatigue and
chemotherapy
cachexia.
6/3/2009 25-09-2009 Onco A post marketing study to study
the pharmacokinetic
parameters of Factor VIII in
patients with Haemophilia A
effect of Cetuximab + Folfiri or
Cetuximab + Folfox in patients
with KRAS wild type metastatic
Colorectal Cancer.
11/2/2009 10/2/2009 Onco A Clinical study to evaluate the
effect of Combretastatin A-4
Phosphate in Combination
With Paclitaxel and
Carboplatin in Comparison
1/4/2009 25-03-2009 Onco To compare the efficacy and
With Paclitaxel and
safety of low-dose versus
Carboplatin in Anaplastic
standard-dose Filgrastim in
Thyroid Carcinoma patients.
chemotherapy induced
Neutropenia.
27-03-2009 30-04-2009 Onco A clinical trial to study safety
and effects of P276-00 in
combination with radiation in
patients with recurrent and /or
locally advanced head and neck
cancer
2/4/2009 1/4/2009 Onco A Phase 1b/2 Trial of AMG 479
or AMG 102 in Combination
With Platinum-Based
Chemotherapy as First-Line
Treatment for Extensive Stage
25-05-2009 5/5/2009 Onco An observational study to see
the effect of chemotherapy
(docetaxel+platinum)when
given prior to
surgery/radiotherapy in Locally
5/5/2009 2/11/2009 Onco This study is to evaluate the
advanced breast cancer
safety and tolerability of
patients.
Fluphenazine HCl
Monotherapy in patients with
Relapsed or Relapsed-and-
Refractory Multiple Myeloma
safety and efficacy of NRC-AN-
019 in patients with Chronic
Myeloid Leukemia who are not
responding or intolerant to
21-08-2009 20-05-2010 Onco A clinical trial to evaluate the
Imatinib mesylate
safety and efficacy of talaporfin
sodium (activated locally using
light of a specific wavelength)
on liver metastases in patients
6/11/2009 12/2/2009 Onco Study to evaluate the safety and
with colorectal cancer
efficacy of TULY (rasburicase)
in prevention and treatment of
malignancy-associated
hyperuricemia
effects of Nanoparticle based
Paclitaxel drug, which does not
contain the solvent cremophor,
in advanced breast cancer
7/10/2009 16-09-2009 Onco The purpose of this study is to
evaluate the efficacy (disease
response) and safety of
mapatumumab in combination
with bortezomib and
8/6/2009 1/4/2010 Onco Phase 1 safety, efficacy, and
bortezomib alone in subjects
pharmacokinetic study of
with relapsed or refractory
Paclitaxel nano-dispersion
multiple myeloma (MM).
injection in subjects with
metastatic breast cancer: A
3/9/2009 31-08-2009 Onco A Clinical trial of
randomized, open label, dose-
Investigational Agent in
ranging, active controlled,
Combination With Paclitaxel in
comparative, parallel group,
Subjects With Advanced Solid
and multi-centric study.
Tumors and Breast Cancer
31-03-2010 16-03-2010 Onco A clinical phase III trial to
study and compare the effects
of human Recombinant PTH in
post menopausal female with
Osteoporosis
23-09-2009 2/7/2010 Onco EGF106708 : Phase-III trial
with adjuvant treatment of
patients with ErbB2
overexpressing and/or amplified
breast cancer who have
25-06-2009 25-06-2010 Onco Study Evaluating Bosutinib-
undegone masectomy and have
Exemestane Combination Vs
received at least four cycles of
Exemestane Alone in Post
an approved anthracycline-
Menopausal Women With
based (neo-) adjuvant
Breast Cancer
9/7/2009 1/10/2009 Onco chemotherapy
A Multicenter, regimen.
Open-Label,
Randomized, Phase 2 Study to
Evaluate the Efficacy and
Safety of NKTR-102 (PEG-
Irinotecan) Versus Irinotecan in
6/8/2009 30-06-2009 Onco Study Comparing Bevacizumab
Patients with Second-Line,
+ Temsirolimus Vs
Irinotecan-Naïve, KRAS-
Bevacizumab + Interferon-Alfa
Mutant, Metastatic Colorectal
In Advanced Renal Cell
Cancer (mCRC).
Carcinoma Subjects
23-09-2009 21-06-2010 Onco EGF106903 : Phase-III trial in
women with HER2/Erb2
positive primary breast cancer
using neoadjuvant
chemotherapy.
v04-08-2009 15-12-2009 Onco A clinical trial to study the
pharmacokinetic comparison of
two formulations for
Intravenous Infusion of
Paclitaxel in Indain Patients
15-10-2009 2/7/2010 Onco EGF105485: Tykerb Evaluation
with Metastatic Breast Cancer.
After Chemotherapy (TEACH):
Lapatinib Versus Placebo In
Women With Early-Stage
Breast Cancer
v07-12-2009 7/7/2010 Onco VEG105424 : Study On
Pazopanib When Given With
FOLFOX6 (Fluorouracil,
Oxaliplatin, Leucovorin) Or
CapeOx (Capecitabine,
v06-11-2009 1/1/2007 Onco To access the toxicity and
Oxaliplatin)
efficacy of altered fractionation
radiotherapy without
chemotherapy in
medulloblastoma
14-09-2009 17-08-2009 Onco Radiation Treatment Of
Bladder Cancer With
Tomotherapy/ Intensity
Modulated Radio Therapy
(IMRT)
18-11-2009 8/6/2010 Onco A Study of Neratinib Plus
Paclitaxel Versus Trastuzumab
Plus Paclitaxel as First-Line
Treatment for ErbB-2-Positive
Locally Recurrent or Metastatic
31-08-2009 31-08-2009 Onco A bioequivalence study of
Breast Cancer
Capecitabine tablets in patients
of Locally Advanced or
Metastatic Breast Cancer or
Metastatic Colorectal Cancer
12/7/2010 12/7/2010 Onco IY5511 HCL for chronic
Myelogenous leukemia
25-09-2009 4/2/2010 Onco A clinical trial to study the

effects of two drugs Peg G-CSF
and Grafeel® in the prevention
of reduction in neutrophil
counts in cancer patients caused
28-10-2009 8/1/2010 Onco A phase II trial to study the
by drugs used to treat cancer.
efficacy and safety of a new
drug P276-00 in the treatment
of Mantle Cell Lymphoma
30-09-2009 4/3/2010 Onco Efficacy Study of XL184 in
Adults With Medullary Thyroid
Cancer.

safety and efficacy of Non-
pegylated Liposomal
Doxorubicin (Nudoxa) as
compared to doxorubicin in
14-10-2009 13-10-2009 Onco A phase 3 clinical trial to study
patients with metastatic breast
the long term safety and
cancer.
efficacy of darbepoetin alfa
drug in drug induced anemia
patients.
effect of HKI-272 in subjects
with Advanced breast cancer
20-10-2009 14-10-2009 Onco Phase 1b/2 clinical trial in
patients with cancer to Evaluate
the Safety and Efficacy of First-
line Treatment With
Epirubicin, Cisplatin, and
6/11/2009 24-11-2009 Onco A Phase II study in patients
Capecitabine(ECX) Plus drug
with Extensive-Stage Small Cell
AMG 102.
Lung Cancer.
23-04-2010 21-04-2010 Onco A 24-week with possible

extension, prospective,
ulticentre, randomized, double
blind, placebo-controlled, 2-
parallel group with a
11/19/2009 11/18/2009 Onco A clinical trial to study the
randomization 1:1, Phase III
effect of NRC-AN-019 in
study to compare efficacy and
patients with various cancers.
safety of masitinib at 6
mg/kg/day to placebo in
3/19/2010 3/16/2010 Onco treatment
A Study ofofAVE8062
patients inwith
Smouldering Systemic,
Advanced-Stage Indolent
Soft Tissue
Systemic or
Sarcoma Cutaneous
After Failure of
Mastocytosis with
Anthracycline andhandicap
Ifosfamide
Chemotherapies
prediction of result of
chemotherapy in Acute myeloid
leukemia by evaluating in vitro
DNA damage.
efficacy of probiotic VSL#3 on
chemotherapy-induced
diarrhoea in cancer patients
recieving
12/23/2009 1/1/2007 Onco A Phase 2 clincial trial to
Fluropyrimidines/Irinotecan.
evaluate the Safety and Efficacy
of drug FOLFIRI in
Combination With drugs AMG
479 or AMG 655 Versus
2/22/2010 4/30/2010 Onco A phase 1 study to evaluate the
FOLFIRI for the Second-line
bioequivalence of two
Treatment of KRAS-mutant
formulation of capecitabine
Metastatic Colorectal Cancer
Tablets 500 mg tablets in
patients of Breast Cancer or
3/9/2010 3/5/2010 Onco A study to assess the benefit of
Colorectal Cancer under fed
using growth factors in addition
condition
to antibiotics in children with
febrile neutropenia
4/13/2010 4/9/2010 Onco Imatinib pharmacokinetics and
its correlation with response
and safety in Indian children
and adults with chronic phase
chronic myeloid leukemia.
3/31/2010 6/15/2010 Onco Phase 3 clinical Study to
Compare the Efficacy and
Safety of drug product
Panitumumab and Cetuximab
in Subjects with Previously
5/26/2010 5/19/2010 Onco A clinical trial study of
Treated Metastatic Colorectal
Sunitinib in biliary tract
Cancer.
carcinoma after failure of first
line treatment
5/17/2010 5/13/2010 Onco Phase III, Multi-centre, Double
Blind, Randomized Placebo
Controlled Trial of Aspirin for
Duke C and High Risk Dukes B
Colorectal Cancers
6/29/2010 1/1/2007 Onco A Clinical trial of Infusion of
Nanosomal Docetaxel Lipid
Suspension (Intas
Pharmaceuticals Ltd.) And
Taxotere® in Breast Cancer
7/12/2010 7/2/2010 Onco A phase 2, open-label test-retest
Patients
study to assess the
reproducibility of quantitative
measurements of 18F uptake by
solid tumours using PET
imaging following intravenous
administration of AH111585
(18F) Injection
A Phase IIb RCT of
Neoadjuvant
chemotherapy
Scientific Title ofcomparing T. sample Phase Esti trial total Site 1
Paclitaxel,
StudyWHO* ifosfamide and size duration Sites
Cisplatin with Paclitaxel, no
cisplatin and 5-FU in 100 Phase 2 2 Years 6 Kashyap Nursing
Phase II Safety and Home
Patients with Locally
Efficacy Study of the
Advanced Head and Neck
Monoclonal Antibody
(H&N) Cancer .
CT-011 in Patients with
Diffuse Large B-Cell 68 Phase 2 915 Days 4 Gujarat Cancer and
Phase III Randomized Research Institute
Lymphoma multinational,
A following
Trial of Maintenance
Autologous StemDouble-
Randomized, Cell
Pegylated Liposomal
Transplantation
Blind Study Comparing
Doxorubicin (PLD) /
Aflibercept Versus Phase 3 Months 1 St. John's Medical
Carboplatin versus
Placebo in Patients College & Hospital
without in Patients with
Treated with Second Line
Advanced Ovarian
Docetaxel after Failure of
Cancer
One Platinum Based
Therapy for Locally 900 Phase 3 1 Orchid Nursing
Advanced or Metastatic Home
Phase II study of
Non Small Cell Lung
Concurrent
Cancer (NSCLC)?.
Chemoirradiation with
weekly Paclitaxel and 25 Phase 2 9 Months 1 Department of
Cisplatin in the treatment Radiation Oncology
of Carcinoma of the Unit I,CHRISTIAN
?Study on the efficacy of MEDICAL
Cervix
Praneem Cream, COLLEGE
Praneem Polyherbal 20 Phase 2 3 Years 1 Cancer Clinic,
Phase II study of 3- VELLORE
tablets on HPV infection Department of
Dimensional conformal Obstetrics & Gynae
of the Cervix-uteri: A
Radiotherapy (3D-CRT)
Pilot study.?
vs. Intensity Modulated
Radiotherapy (IMRT) for 60 Phase 2 Years 1 Dept. of Radiation
Squamous Cell Oncology
Carcinoma of the Head
Head Shaving in
and Neck (HNSCC)
Neurosurgery ?
Implications on Surgical 46 Not Years 1 Department of
A randomized double Applicable surgical oncology,
Site Infection and
blind study of efficacy of ACTREC & TMC
Cosmesis ? a feasibility
Lactobacillus CD2
study
lozenges in preventing
radiation and 300 Phase Years 1 Institute Rotary
chemotherapy induced 2/Phase 3 Cancer Hospital, All
oral mucositis in head India Institute of
and neck cancer. Medical Sciences,
New Delhi-110029
A Phase II Safety and
Efficacy Study of
Bavituximab Plus
Paclitaxel and
An open label,
Carboplatin in Patients
multicenter Phase II 49 Phase 2 24 Months 6 Orchid Nursing
with Previously Untreated
study to evaluate efficacy Home, Kolkata
Locally Advanced or
and safety of P276-00 in
Metastatic Non-Small-
Indian subjects with
Cell Lung Cancer.
recurrent, metastatic or
unresectable locally 54 Phase 2 Years 7 Central India Cancer
advanced squamous
A Multinationalcell Research
An Open Label, Institute,11,Shankar
carcinoma of head
Randomized and
Double
Multicenter Phase I Study Nagar, West High
neck Placebo-controlled
Blind,
Of Selective Cyclin Court Road,Nagpur -
study to evaluate the Phase 1 Years 5 Bhagwan Mahaveer
Dependent Kinase 440010
efficacy and safety of Cancer Hospital,
Inhibitor
A phase P1446A-05
II study In to
AVE5026 in the JLN Marg, Jaipur
Subjects With
determine theAdvanced
safety,
prevention of Venous 302017
Refractory Malignancies
efficacy, and
Thromembolism(VTE) in
pharmacokinetics of 3200 Phase 3 2 Years 2 Jaslok Hospital and
cancer patients at high
multiple intravenous Research Centre
risk for VTE and who are
doses of ald518 80 mg,
undergoing
160 mg, and 320 mg
chemotherapy
versus placebo
administered to patients Phase 2 Years 13 Tata Memorial
An Open, Prospective, Hospital
with non-small cell lung
Non-comparative,
cancer-related
An Asia Pacificfatiguenon-
and
Multicenter
A Multicenter, StudyOpen- to
cachexia.
randomized, open-label
Estimate the
Label, recovery
Randomized,
phase II study evaluating Phase 4 3 Christian Medical
after a single
Phase II/III infusion
Study to of
the safety and efficacy of College
Human the
Evaluate Factor
Safety VIII
and
FOLFIRI plus cetuximab
Factocel 250 I.U. in
Efficacy of
(Erbitux) or FOLFOX
patients of Haemophilia
Combretastatin A
A-4
plus cetuximab as first-
Phosphate in 260 Phase 2 4 Years 5 Rajiv Gandhi Cancer
line therapy in subjects
Combination With Institute & Research
with KRAS wild-type
Paclitaxel and Centre
metastatic Colorectal
Carboplatin in
cancerrandomized
A (APEC-Study)open
Comparison With
labeled parallel group 180 Phase 3 Years 8 Mediciti Hospital,
Paclitaxel and
phase III study of low- 2/Phase 3
Carboplatin
An Open Against
Label,
dose versus standard-dose
Anaplastic
Multicenter PhaseThyroid
I/II
granulocyte colony
Carcinoma
Study Of Selective Cyclin
stimulating factor
Dependent Kinase 172 Phase 3 2 Years 1
prophylaxis in pediatric
Inhibitor P276-00 In
cancer patients receiving
Combination With
myelosuppressive
Radiation In Subjects
chemotherapy.
With Recurrent And/Or
Locally Advanced Phase Months 6 V. N. Cancer Centre
Squamous Cell 1/Phase 2
Carcinoma Of Head And
Neck
A Phase 1b/2 Trial of
AMG 479 or AMG 102 in
Combination With
Platinum-Based
Chemotherapy as First- 204 Phase 3 Kidwai Memorial
Line Treatment for 1/Phase 2 Institute of Oncology
Extensive Stage Small
Cell Lung Cancer
Neo-Adjuvant Docetaxel
plus Platinum for Locally 100 Not 1 Years 5 Birla Cancer Center,
Advanced Breast Cancer Applicable SMS Medical College
Phase 1b Single Arm, Hospital
(LABC): A single arm
Open Label, Multi-Center
Observational Study.
Study of Fluphenazine
HCl Monotherapy in Phase 1 Years 8 Tata Memorial
An open label, Phase I Hospital
Relapsed or multicenter,
A Relapsed-
dose escalation clinical
and-Refractory phase
multinational Multiple3
trial of NRC-AN-019 in
Myeloma
randomized study to
patients with all phases of
evaluate the safety and 40 Phase 1 12 Months 2 Department of
Chronic Myeloid
efficacy of treating Medical Oncology
Leukemia, who are
colorectal cancer patients
resistant or intolerant to
with recurrent liver
Imatinib mesylate
metastases using the
LitxTM system plus 450 Phase 3 2 Years 9 Site No. 0791,
chemotherapy as Bangalore Institute
Efficacy and safety of of Oncology
compared to
TULY (rasburicase) in
chemotherapy alone
prevention and treatment
of malignancy-associated 100 Phase 3 6 Months 5 2. MNJ Institute of
hyperuricemia
A - An open-
Phase 2, Multi-Center, Oncology and
label, multicentre
Open-Label, study in
Randomized Regional Cancer
India. of Mapatumumab
Study Center
A Multicentre Phase I
(TRM-1 [HGS1012], a 24 Phase 1 1 Years 3 Kidwai Memorial
Study Of Cremophor
Fully Human Monoclonal Institute of Oncology
FreePaclitaxel
Antibody to TRAIL-R1)
Nanoparticle
Phase In
1 safety, efficacy,
in Combination With
Advancedpharmacokinetic
and Breast Cancer.
Bortezomib (Velcade) and
study of Paclitaxel nano- 100 Phase 2 4.5 Years 4 Rajiv Gandhi Cancer
Bortezomib Alone in
dispersion injection in Institute & Research
Subjects With Relapsed
subjects with metastatic Centre
or Refractory Multiple
breast cancer: A
Myeloma
randomized, open label,
dose-ranging, active 25 Phase 1 12 Months 6 Shatabdi
controlled, comparative, Superspeciality
parallel group, and multi- Hospital, Nashik
A Phase I/II Study of
centric study.
HKI-272 in Combination
With Paclitaxel in 93 Phase 22 Months 4 Maharashtra
Subjects With Advanced 1/Phase 2 Medical
Solid Tumors and Breast Foundation's (MMF)
Cancer Joshi Hospital
study to compare the
Safety and efficacy of
Teriparatide
EGF106708 : A
[recombinant human
Randomised, Multi-
parathyroid hormone (1-
Centre, Open-Label,
34)] of Intas
Phase III Study of 120 Phase 3 11 Months 13 NRN Orthopaedic
Biopharmaceuticals Ltd.
Adjuvant Lapatinib, Clinic
against
A PhaseForteo of Eli-Lilly
2, Randomized,
Trastuzumab, Their
in
Open-Label postmenopausal
Study of
Sequence and Their
females withAdministered
Bosutinib Osteoporosis
Combination in Patients
in Combination With 8000 Phase 3 7 All India Institute of
With HER2/ErbB2
Exemestane Versus Medical Sciences
Positive
A Primary Breast
Multicenter, Open-
Exemestane Alone as
Cancer. Acronymn
Label, Randomized,-
Second Line Therapy in
ALTTO
Phase 2 Study to Evaluate
Postmenopausal Women
the Efficacy and Safety of Phase 2 Months 7 Tata Memorial
With
A PhaseLocally Advanced
3b, Randomized,
NKTR-102 (PEG- Centre
or
Open-Label Metastatic
Study of
Irinotecan) Versus
ER+/PgR+/ErbB2- Breast
bevacizumab
Irinotecan
EGF106903 in : Patients Neo
Cancer
(AVASTIN®) +
with
ALTTO Second-Line,
(Neoadjuvant
temsirolimus Phase 2 Months 11 Hemato-Oncology
Irinotecan-Naïve, KRAS-
Lapatinib and/or
(TORISEL®) vs. Clinic Ahmedabad
Mutant,
Trastuzumab Metastatic
Treatment
bevacizumab Pvt.Ltd.
Colorectal
Optimisation) Cancer
Study A
(AVASTIN®) +
(mCRC).
Randomised, Multicenter
interferon-alfa
Open-Label Phase III 800 Phase 3 48 Months 9 SEAROC Cancer
(ROFERON®)
An as First-
open label, balanced,
Study of Neoadjuvant Centre
Line Treatment
randomized, two period,in
Lapatinib, Trastuzumab
Subjectstreatment,
two with Advanced two
and Their Combination
Renal Cell Carcinoma
sequence, and two way
Plus Paclitaxel in Women
crossover study to 450 Phase 3 6 Ruby Hall Clinic-
With HER2/ErbB2
evaluate safety and Cancer Centre
Positive Primary Breast
pharmacokinetic
Cancer. Acronymn - NEO
comparison of
ALTTO
intravenous infusion of
EGF105485: A Phase 1 4 M S Patel Cancer
paclitaxel Lipid
Randomized, Double- Centre
Suspension and Taxol® in
Blind, Multicenter,
patients with Metastatic
Placebo-Controlled Study
Breast Cancer
of Adjuvant Lapatinib
(GW572016) in Women 3000 Phase 3 7 Ruby Hall Clinic-
VEG105424 : An Open- Cancer Centre
With Early-Stage ErbB2
Label, Pharmacokinetic
Overexpressing Breast
Study of the Safety and
Cancer
Tolerability of Pazopanib
in Combination With 70 Phase 1 2 NIMS,Medical
FOLFOX 6 or CapeOx in Oncology Dept.
Optimizing the physical
Subjects With Colorectal
and biological parameters
Cancer
in craniospinal
irradiation (CSI) for 20 Phase 36 Months 1 Advanced Centre for
average risk 1/Phase 2 Treatment Research
medulloblastoma: a and Education
feasibility study.
randomized, open label,
two-period, two-
treatment, two-way
crossover, bioequivalence
Feasibility
study Study
comparing
A Phase 3, Randomized,
Evaluating
Capecitabine Bladder
tablets 500
Open-Label, Two-Arm 20 Not 2 Years 1 Tata Memorial
Preservation
mg By Helical
(Manufactured by
Study of Neratinib (HKI- Applicable Centre
Tomotherapy
Intas Based
Pharmaceuticals
272) Plus Paclitaxel
IMRT InIndia)
Ltd., Muscle to Invasive
the
Versus Trastuzumab Plus
Bladder Cancer
reference listed drug
Paclitaxel as First-Line
XELODA® 500 mg 1200 Phase 3 Months 13 Tata Memorial
Treatment for ErbB-2-
tablets (Manufactured by Hospital
Positive Locally
Roche Pharma AG,
Recurrent or Metastatic
Germany) in patients of
Breast
A Phase Cancer
I/II multicenter
Locally Advanced or
study of IY5511HCI in 30 Phase 1 5 Months 16 Curie Manvata
Metastatic Breast Cancer
Philadelphia chromosome Cancer centre, Opp.
or Metastatic Colorectal
positive chronic myeloid Mahamarg Bus
Cancer under fed
leukemia patients without stand, Mumbai
condition
optimal response or Naka, Nashik,
A randomized, multi- 20 Phase 18 Months 2 Dept. Of Medical
tolerance to Bcr-Abl Maharashtra-422004
center, open label study to 1/Phase 2 Oncology, Prince Aly
tyrosine kinase inhibitors
evaluate the efficacy and Khan Hospital
(Imatinib and/or
safety of Peg G-CSF as
Dasatinib, Nilotinib)
compared to Grafeel® in
the prophylaxis of severe 150 Phase 3 21 Months 14 Amrita institute of
neutropenia in cancer medical sciences
patients receiving
cytotoxic chemotherapy.
Single-Arm, Open-Label, Phase 2 Years 6 Tata Memorial
Multicenter Phase II Hospital, Dr. E.
Study to Evaluate the Borges Marg, Parel,
Efficacy and Safety of Mumbai-400012
P276-00 in Patients With
An International, Phase 3 Months 9 All India Institute of
Relapsed and/or
Randomized, Double- Medical Sciences
Refractory Mantle Cell
Blinded, Phase 3 Efficacy
Lymphoma
Study of XL184 versus
Placebo in Subjects with
A phase II/III Open label Part A:12, Phase Two Years 6 Jaslok Hospital
Unresectable, Locally
Multicentric Randomized 2/Phase 3
Advanced, or Metastatic
trial to determine the
Medullary Thyroid
safety and efficacy of
Cancer.
Non-pegylated Liposomal
A Randomized, Double- 3000 Phase 3 10 Years 20 IRL Research
Doxorubicin (Nudoxa) at
blind, Placebo-controlled Centre,
two different dose levels
Study to Evaluate the
as compared to
Long-term Safety and
doxorubicin in patients
Efficacy of Darbepoetin
with metastatic
Phase 2 Study ofbreast
HKI-272 122 Phase 2 3 Years 4 Nizam's Institute of
Alfa Administered at 500
cancer.
in Subjects with Medical Sciences
µg Once-Every-3-Weeks
Advanced Breast Cancer
in Anemic Subjects With
Advanced Stage Non-
small Cell Lung Cancer
Receiving Multi-cycle
Chemotherapy
A Multicenter, Double- 136 Phase 4 Years 6 Tata Memorial
Blind, 3-Arm, Phase 1b/2 1/Phase 2 Hospital
Study in Subjects With
Unresectable Locally
Advanced or Metastatic
A Phase I Followed by a 154 Phase 2 Months 11 G Kuppuswamy
Gastric or
Randomized, Phase II Naidu Memorial
Esophagogastric Junction
Study of Carboplatin and Hospital
Adenocarcinoma to
Etoposide with or without
Evaluate the Safety and
Obatoclax Administered
Efficacy
A 24-weekof with
First-line
possible 200 Phase 3 30 Months 19 Choithram Hospital
Every 3 Weeks to Patients
Treatmentprospective,
extension, With and Research Centre
with Extensive-Stage
Epirubicin,randomized,
ulticentre, Cisplatin, and
Capecitabine(ECX)
double blind, placebo- Plus
(ES-SCLC)
AMG 102 2-parallel
controlled,
A Phase-I Clinical Study 72 Phase 1 1 Years 2 Krishna Institute of
group with a
to Evaluate the Safety, Medical Sciences
randomization 1:1, Phase
Pharmacokinetics and
III study to compare
Anti-Tumor Activity of
efficacy and safety of
NRC-AN-019 in Patients
masitinib
A at 6 mg/kg/day
multinational, 300 Phase 3 3 Years 4 FR. Muller Hospital
with Solid Tumors.
to placebo in double-blind
randomized, treatment of Department of
patients controlled
placebo with study Radiation Oncology
Smouldering
of AVE8062 (25 Systemic,
mg/m²)
Indolent Systemic
administered everyor3
In vitro DNA damage 30 Not 2 Years 1 Department of
Cutaneous
weeks, Mastocytosis
in patients with
assessment as predictor of Applicable Pharmacology and
with handicap soft tissue
advanced-stage
response to chemotherapy Department of
sarcoma treated with
in acute myeloid Medical Oncology,
cisplatin (75 mg/m²) after
leukemia. AIIMS, New Delhi
failure
A phaseofIIanthracycline
/ III, 242 Phase 2 Years 1 All India Institute of
and ifosfamide
randomized, double- 2/Phase 3 Medical Sciences
chemotherapies.
blind, placebo controlled
study to investigate the
efficacy of a probiotic
A Phase 2, Randomized, 150 Phase 2 4.5 Years 5 Kidwai Memorial
VSL#3®, on
Double-blind, Placebo- Institute of Oncology
Chemotherapy-induced
controlled Study
diarrhoea in cancer
Evaluating the Safety and
patients receiving
Efficacy of FOLFIRI in
Fluropyrimidines
A multicentre, 110 Not 06 Months 10 Noble Hospital
Combination With AMG
/Irinotecan open label,
randomized, Applicable (Oncology
479 or AMG 655 Versus
two-period, two- Department),153,
FOLFIRI for the Second-
treatment, two-way Magar patta, City
line Treatment of KRAS-
crossover, bioequivalence Road,Pune-411013
mutant
A Metastatic
randomized open 200 Phase 3 2 Years 1 Tata Memorial
study comparing
Colorectal
labeled Carcinoma
parallel group Hospital
Capecitabine Tablets USP
phase III study of
500 mg (Manufactured
antibiotics alone versus
by: Intas Pharmaceuticals
antibiotics plus
Ltd., India) to the
granulocyte-colony-
reference listed drug
stimulating factor in
Xeloda® (capecitabine)
pediatric patients with
Tablets 500 mg
chemotherapy induced
(Distributed by: Roche
febrile neutropenia in a
Laboratories Inc., New
developing country.
Jersey 07110) in patients
of Breast Cancer or
Colorectal Cancer under
A Randomized, 68 Not 2 Years 1 Department of
Multicenter, Open-label, Applicable Medical Oncology
Phase 3 Study to
Safety of Panitumumab
A Randomized, 60 (India) Phase 3 4 Years 9 Kidwai Memorial
and Cetuximab in
Multicenter, Open-label, Institute of
Subjects with Previously
Phase 3 Study to Oncology,
Treated, Wild-type
KRAS, Metastatic
Safety of Panitumumab
Colorectal
Aspirin forCancer
Duke C and 59 Phase 2 18 Months 1 Rajiv Gandhi Cancer
and Cetuximab in
High Risk Dukes B Institute & Research
Subjects with Previously
Colorectal Cancers. An Centre
Treated, Wild-type
International, Multi-
KRAS, Metastatic
centre, Double Blind,
Colorectal
Aspirin forCancer
Duke C and 2660 Phase 3 8 Years 4 Department of
Randomized Placebo
High Risk Dukes B Medical Oncology,
Controlled Phase III Trial
Colorectal Cancers. An Kidwai Memorial
International, Multi- Institute of
centre, Double Blind, Oncology, Hosur
An Open Label, 72 Phase 2 17 Months 6 IndoAmerican
Randomized Placebo Road
Randomized, Multiple- Cancer
Controlled Phase III Trial
Dose, Parallel Study To Hospital,Road No.
Evaluate The Safety And 14, Banjara Hills,
Efficacy Of Intravenous Hyderabad
A phase 2, open-label test- upto 45 Phase 2 24 Months 2 Manipal Hospital,
Infusion of Nanosomal
retest study to assess the
Docetaxel Lipid
reproducibility of
Suspension (Intas
quantitative
Pharmaceuticals Ltd.)
measurements of 18F
And Taxotere®
uptake by solid tumours
(Docetaxel Injection
using PET imaging
Concentrate, Aventis
following intravenous
Pharma Ltd.) in Locally
administration of
Advanced or Metastatic
AH111585 (18F) Injection
Breast Cancer Patients
after failure of prior
chemotherapy
Site 2 Site 3 Site 4 Site 5
INHS Ashwini Dinanath Mahavir Cancer O P Jindal Institute

Hospital Mangeshkar hospital Hospital
Jaslok Hospital and Rajiv Gandhi Cancer Deenanath

Research Centre, Institute and Mangeshkar
Dept. of Oncology, Research Centre, Hospital and
15, Dr. G. Department of Research Centre,
Department of
Kidwai Memorial Medical College, Apollo Hospital, Yashoda Hospital,
Institute of Kozhikode Bangalore Hyderabad
Oncology, Bangalore
Dept. Of Surgical Division of Head & Bhagwan Mahaveer Bharath Hospital &
Oncology, CSM Neck Cancer Hospital & Institute of
Medical University, Oncology,Regional Research Oncology,Outer Ring
King george Medical cancer Centre,Dept. Of Road,438 - Hebbal,
University, Lucknow Centre,Medical Medical Mysore - 570017
Jehangir Hospital, Ruby Hall Clinic, SEAROC Cancer Tata Memorial
- 226003 College Campus, Oncology,Jawahar
32, Sassoon Road, New Cancer Bldg., Centre, S. K. Soni Centre, Department
Trivandrum - 695011 Lal Nehru Marg
Pune 411001 3rd Floor, 40, Hospital, Sec-5 of Medical Oncology,
Sassoon Road, Pune Vidhyadhar Nagar, Dr. Ernest Borges
411 001. Sikar Road, Jaipur Road, Parel ,
Sri Ganga Ram
302013 Mumbai -400012
Hospital
Kidwai Memorial Shatabdi Hospital SEAROC Cancer Jehangir Clinical

Institute of Oncology Center Development Centre
Pvt. Ltd.
St. Johns Medical King Edward

College & Hospital Memorial Hospital
Sir Ganga Ram S. L. Raheja Hospital Tata memorial All India Institute of
Hospital hospital Medical sciences
All India Institute of Shirdi Sai Baba Apollo Cancer Ruby Hall Clinic
Medical Sciences Cancer Hospital Institute
Katsurba Medical
College & Hospital
Manipal
Bhagwan Mahawir Government Medical Christian Medical Curie Manavata

Cancer Hospital & College College Cancer Center
Research Centre
S. K. Soni Hospital Tata Memorial
Centre
Kashyap Nursing Sparsh Hospitals and Bhagwan Mahaveer Mahaveer Cancer

Home Critical care (p) ltd Cancer Hospital & Sansthan
Research Centre
Netaji Subhash Indira Gandhi Max Super Specialty Kidwai Memorial

Chandra Bose Institute of Medical Hospital Institute of Oncology
Cancer Research Sciences
Institute
Department of
Hematology, All
India Institute of
Medical Sciences
Site No. 0789, Tata Site No. 0787, Site No. 0792, Site No. 0793,
Memorial Hospital, Regional Cancer Mahaveer Cancer Jawaharlal Nehru
Centre Sansthan Cancer Hospital and
Research Center
1. Bangalore 3. NIMS Hospital 4. Indo-American 5. King George
Institute of Oncology Cancer Institute and Hospital, Andhra
Research Center Medical College
Nizam's Institute of SEAROC Cancer

Medical Sciences Center
All India Institute of Bangalore Institute Bharath Hospital &

Medical Sciences of Oncology Institute of Oncology
KEM Hospital, pune Manavata Curie Kailash Cancer Apollo Hospital,

Research centre Hospital, Goraj Ahmedabad
Birla Cancer Centre Jehangir Clinical Tata Memorial

Development Centre Centre
shreeji Orthopedic Sushrut Hospital Yash Hospital 95/B,Siddhatek
and ENT Hospital Appartments,
Central India Cancer Apollo Hospital Tata Memorial NIMS, Department

Research Institute Educational and Hospital of Medical Oncology
Research
SEAROC Cancer Jawaharlal Nehru Jehangir Clinical Kaushalya Medical

Centre Cancer Hospital & Development Centre Foundation Trust
Research Centre Private Limited Hospital
Chittaranjan Curie Manavata Kodlikeri Memorial Rajalakshmi

National Cancer Cancer Centre Hospital Multispeciality
Institue Hospital
Apollo Speciality Hemato-Oncology Jawaharlal Nehru Jehangir Clinical

Hospital Clinic Ahmedabad Cancer Hospital & Development Centre
Pvt. Ltd Research Centre Private Limited
Tata Memorial Nizam's Institute of Apollo Hospital's vCentral India

Hospital Medical Sciences Educational & Cancer Research
Research Foundation Institute
(Spectra Clinical
Research)
Jeevandip Hospital Mahavir Cancer Meeneakshi Mission
Sansthan Hospital and Rearch
Centre
Tata Memorial All India Institute of Nizam's Institute of SEAROC Cancer

Hospital Medical Sciences Medical Sciences Centre
Tata Memorial
Hospital
Jawaharlal Nehru Birla Cancer Centre, SEAROC Cancer Central India Cancer
Cancer Hospital & SMS Medical College Centre, S.K. Soni Research Institute
Research Centre and Hospital Hospital
Deenanath Ruby Hall Clinic 40 , Meeneakshi Mission PSG Institute of

Mangeshkar sasoon Road, Pune- Hospital and Rearch Medical Sciences &
Hospital, 411001 Centre, Lake Area, Research,Off
Erandwane, Pune- Melur Road, Avanashi Road,
411004 Maharashtra Madurai - 625107 Peelamedu,Coimbato
Department of
re - 641 004
medical Oncology
Lakeshore Hospital Apollo Specialty Indo American Nizam's Institute of

& Research Centre Hospital Cancer Institute and Medical Sciences
Ltd Research Centre
Cancer Care Clinic Institute Rotary Malabar Institute of St. Johns Medical
and Hospital, 5th Cancer Hospital, All Medical Sciences, College & Hospital,
floor, Vasant Sheela India Institute of Govindapuram, Sarjapur Road,
Tower, Lokmat Medical Sciences, Calicut, Kerala- 16 Bangalore 34
Square, Nagpur- New Delhi 110029
Deenanath Ruby Hall Clinic Shatabdi Kidwai Memorial
440012
Mangeshkar Superspeciality Institute Of
Hospital & Research Hospital Oncology
Center
The Gujarat Cancer Vedanta Institute of Dharamshila B.L. Kapur
& Research Institute Medical Sciences Hospital and Memorial Hospital,
research centre
Kidwai Memorial Jewaharlal Nehru Govt Medical College MNJ Institute of

Institute of Oncology Cancer Hospital and and Hospital Oncology
Research Centre
Jehangir Hospital Tata Memorial Deenanath

Hospital Mangeshkar
Hospital and
Research Centre
Kidwai Memorial Jawaharlal Nehru Indo-American Curie Manavata
Institute of Oncology Cancer Hospital Cancer Institute & Cancer Centre
Research Centre
Acharaya Harihar Jawaharlal Nehru Curie Manavata Orchid Nursing

Regional Cancer Cancer Hospital & Cancer Centre Home
Centre Research Centre
St. John's Medical Deccan College of Kothari Skin Centre LTM medical college
College and Hospital Medical Sciences & LTM general
hospital
Nizams Institute of
Medical Sciences
Apollo Hospitals India Apollo Gokula Metropolis

Hospital, Education Clinical Research
& Research Cente
Foundation (Spectria
Clinical Research),
Tata Memorial MNJ Institute of Jawaharlal Nehru Shatabdi Hospital

Hospital Oncology Cancer Hospital and
Research Centre
Central India Cancer Manvata Curie Shatabdi Hospital, Dr.Rai Memorial

Research Centre, 11 Cancer centre, Opp. Suyojit City Medical Centre, No:
Shankarnagar, Mahamarg Bus Center,Mumbai 562 - Century Plaza,
Nagpur-440011, stand, Mumbai Naka, Nashik, Teynampet,Chennai
India Naka, Nashik, Maharashtra-422005 - 600018
Maharashtra-422004
Shatabdi Hospital, Curie Manavata MNJ Institute of Indo-American
Cancer Centre, oncology and Cancer Institute &
Research Cancer Research Centre
Centre,
Regional Cancer Tata Memorial Dr. B.R.A Institute

Centre Hospital Rotary Cancer
Hospital, AIIMS,
Ansari Nagar
Shalby Hospital, Moolchand Medcity, CHL Apollo "Additional
Opp. Karnavti Club, Main Ring Road, Hospital, Nr. L.I.G Professor, Breast
S G High way, Lajpatnagar III, New Triangle, A.B. Road, Cancer
Ahmedabad Delhi Indore. M.P. Clinic,Regional
Cancer
Bangalore Institute
Centre,Trivandrum
of Oncology,
Site 6 Site 7 Site 8 Site 9
Sanchetee Hosp &

Cancer Inst
Nizam's Institute of
Medical Science,
Hyderabad
Jaslok Kashyap Nursing

Hospital,15,Dr.G.Des Home, Imperial
hmukh Marg,Peddar mahal, Dadar TT.
Road,Mumbai- Mumbai - 14
400026
Curie Manavata Dr Kamakshi GKNM Hospital, GKNM Hospital,

Cancer Centre, Memorial Hospital
Tata Memorial Kidwai Hospital Christian Medical

Hospital College
Meenakshi Mission
Hospital & Research
Centre
Amrita Institute of M.S. Ramaiah Malabar Institute of
Medical Sciences Medical College and Medical Sciences
Teaching Hospital
Site No. 0784, Site No. 0786, Site No. 0785, Cancer
Shatabdi Super SEAROC Cancer Clinic, Shreevardhan
Specialty Hospital Center, S. K. Soni complex
hospital
Denananath
Mangeshkar
Hospital, Pune
Gandhi Orthopaedic Aakar Hospital Jivani orthopedic, Princess Durru
Hospital arthroscopy hospital Shehwar Hospital
Netaji Subhash Regional Cancer

Chandra Bose Center
Cancer Research
Institute
Curie Manavata Dharamshila
Cancer Centre Hospital and
Research Centre
M.S. Ramaiah B.P. Poddar Hospital Mehendi Nawaz Amrita Institute of

Memorial Hospitial and Medical Jung Institute of Medical Sciences
Research Ltd. Oncology and
Regional Cancer
Centre
Bangalore Institute Lakeshore Hospital Regional Cancer Tata Memorial
of Oncology and Research Centre Centre Centre
Ltd.,
Kidwai Memorial
Institute of Oncology
Apollo Speciality Jehangir Hospital

Hospital and Medical Centre
Curie Manavata Meenakshi Mission B P Poddar and Shatabdi Super
Cancer Centre Hospital and Medical Research Speciality Hospital
Research Centre Ltd.
Department of Netaji Subhash Dept. of Medical Mahavir Cancer

Radiotherapy, Chandra Bose Oncology, M S Patel Sansthan, Phulwari
Christian Medical Cancer Research Cancer Centre, Sharif, Patna
College,IDA Scudder Institute, 16A, Park Shree Krishna
Road,Vellore - 632 Lane, Kolkata-16 Hospital, Gokal
001. Nagar, Karamsad
Jaslok Hospital Asian Institute of Joshi Hospital Jawaharlal Nehru

Oncology, S.L. Cancer Hospital &
Raheja Hospital Research Centre
Meenakshi mission
hospital and research
centre
Netaji Subhash The Indo-American Central India Cancer SEAROC Cancer

Chandra Bose Cancer Institute & Research Institute Centre
Cancer Research Research Centre
Institute
Sheth Nandlal Dhoot
Hospital
Kaushalya Medical Pravara Institute of Ruby Hall Clinic Indo-American

Foundation Trust Medical Sciences Cancer Institute &
Hospital Research Centre
Amrita Institute of
Medical Sciences &
Research Centre,
Orchid Nursing Tata Memorial Dr. Kamakshi Noble Hospital

Home Hospital Memorial Hospital
178-Dh Sector Government Cancer Cancer Clinic Smt. S. C. L.

Hospital Hospital
Meeneakshi Mission Cancer hospital & Dept. of Medical Mahavir Cancer

Hospital,Melur research institute, Oncology, M S Patel Sansthan, Phulwari
Road, Madurai - Regional Centre for Cancer Centre, Sharif, Patna
625107 Cancer Research & Shree Krishna
Treatment, Cancer Hospital, Gokal
hill, Mandre ki mata, Nagar, Karamsad
Gwalior - 474 009.
Madhya Pradesh.
India
Rural Medical Department of Deenanath S. K. Soni Hospital
College, PIMS Medical Oncology, Mangeshkar
Hospital
"Lions Cancer
Detection Center,
New Civil Hospital,
Majura Gate, Surat,
Gujarat.
Site 10
Orchid Nursing IndoAmerican Mahavir Cancer Indira Gandhi
Home Cancer Institute & Sansthan Institute of Medical
Research Center Sciences
Madhu Orthopaedic Dia Care Research Karne Hospitals Orthopaedic Clinic
Fracture & Accident Private Limited
Hospital,
Shatabti Kaushalya Medical

Superspeciality Foundation Trust
Hospital Hospital
Dayanand Medical Institute Rotary Deenanath Christian Medical
College & Hospital Cancer Hospital, All Mangeshkar College
India Institute of Hospital and
Medical Sciences Research Centre
M.D. Oswal Cancer Jeevandeep Hospital, Kaushalya Medical
Treatment & Station Road , Surat Foundation Trust
Research Hospital.Thane (w)-
Foundation, G.T 400601
Road, Sherpur by
pass, Ludhiana.
Hemato-Oncology Artemis Medicare Dayanand Medical Orchid Nursing

Clinic, Vedanta Services Pvt Ltd College & Hospital Home
Institute of Medical
Science
S. K. Soni Hospital, Seth Nandlal Dhoot A.H.Regional Cancer LRS Instiute of TB &
Hospital Center Respiratory diseases
Hemato Oncology Galaxy Cancer
Clinic Institute
B.J.Medical college Sheth V. S. Hospital New civil hospital Gandhi Medical

&. N. H. L- College
Municipal Medical
College
Jeevandeep Hospital,
302, 3rd floor, Ayush
Doctor House,
Station Road, Surat
V.S. Hospitals Pvt.
Ltd.
Chhatrapati Shauji Jehangir Hospital SMS Medical College Curi Manavata

Maharaj Medical Hospital Cancer Centre
University
University College of Shri B.M.Patil Amrita Institute of Govt. Medical
Medical Sciences & Medical College Medical Sciences and College
GTB Hospital Research Centre
Lakeshore Hospital Shri Sidhivinayak Tata Memorial
& Research Centre Ganapati Cancer Centre
Ltd Hospital
Dayanand Medical
College & Hospital
S. no Trial UTRN.WHO CTRI No.and Date
1 trial 1 TEMP UTRN 123314078- CTRI/2008/091/000309,

31122008411821 16-01-2009
2 trial 2 TEMP UTRN 093845302- CTRI/2009/091/000013,

09012009425431 01-12-2009
3 Trial 3 TEMP UTRN 052227973- CTRI/2009/091/000043,

28012009460856 13-10-2009

11032009513970 01-07-2009
5 Trail 5 TEMP UTRN 110650739- CTRI/2009/091/000976,

2311200914682002 30-12-2009

2611200914821953 08-12-2009

29052009766602 17-06-2009

070520096911045 15-09-2009

180720091034856 13-01-2010
1008200910981953 17-09-2009

110820091102602 24-09-2009

2808200911561804 17-11-2009

10112009142427 24-02-2010

3012200915861804 17-02-2010

1901201016731444 16-02-2010

0904201019671078 18-05-2010

1604201020103408 04-06-2010

1201201016461032 05-02-2010

0503201018261444 22-06-2010

2203201019002629 11-05-2010
1705201021413503 08-07-2010

24062009898599 27-07-2009

10102008300599 01-01-2009

10102008301599 11-02-2009

21122008400346 27-05-2009

28012009460856 13-10-2009

11032009513970 01-07-2009

29052009766602 17-06-2009

03062009782602 17-06-2009

070720099881728 11-08-2009

25062009919602 06-08-2009
32 Trial 32 CTRI/2009/091/000681, 17-09- CTRI/2009/091/000681,
2009 17-09-2009

0309200911821247 11-09-2009

3009200912861009 11-12-2009

10112009142427 24-02-2010

020220101719602 15-04-2010

0802201017432868 09-03-2010

2704201020623444 19-05-2010

30122008408741 05-02-2009

200320095291096 10-06-2009

1105201021203247 19-05-2010

31122008411821 16-01-2009
31122008411821 16-01-2009

21102008310637 02-07-2009

2807200910581889 11-08-2009

080620097971475 08-07-2009

200620098641475 06-07-2009
48 Trial 48
49 Trial 49
50 Trial 50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
Speciality-
Status of TrialWHO Last Verified on Last Updated on
Subspeciality
Not yet recruiting

1/16/2009 1/16/2009 ACS
Closed to recruitment
follow up continuing &
closed to recruitment 12/1/2009 7/7/2010 ACS
follow up complete fully
Open to recruitment
10/13/2009 6/25/2010 ACS
Terminated
7/1/2009 10/21/2009 ASC
Completed
12/30/2009 6/25/2010 ACS
Open to recruitment
12/8/2009 4/29/2010 ACS
Open to recruitment
6/17/2009 6/8/2010 ACS
Open to recruitment
9/15/2009 10/1/2009 ACS
Open to recruitment
1/13/2010 4/12/2010 ACS
Open to recruitment
9/17/2009 11/20/2009 ACS
Open to recruitment
9/24/2009 11/12/2009 ACS
Open to recruitment
10/30/2009 17-11-1009 ACS
Open to recruitment
2/24/2010 2/16/2010 ACS
Open to recruitment
2/17/2010 02--4-2010 ACS
Open to recruitment
2/16/2010 5/11/2010 ACS
Open to recruitment
2/16/2010 7/6/2010 ACS
Open to recruitment
6/4/2010 6/1/2010 ACS
Open to recruitment
2/5/2010 7/12/2010 ACS
Open to recruitment
6/22/2010 6/25/2010 ACS
Open to recruitment
5/11/2010 5/11/2010 ACS
Open to recruitment
7/8/2010 7/8/2010 ACS
Closed to recruitment of
participants
27-07-2009 23-07-2009 HF
Open to recruitment
1/1/2009 21-04-2010 HF
Open to recruitment 11/2/2009 11/2/2009

HF
Completed 5/27/2009 4/8/2010

HF

HF
Terminated 7/1/2009 10/21/2009

HF

HF

HF

HF

HF
HF

HF
Temporary halt or 12/11/2009 2/25/2010

suspended
HF

HF

HF

HF

HF
Completed 2/5/2009 3/30/2009

IHD
Completed 6/10/2009 6/25/2010

IHD

IHD
Not yet recruiting 1/16/2009 1/16/2009 Unstable Angina

Not yet recruiting 1/16/2009 1/16/2009
Angina
Closed to recruitment of 7/2/2009 7/8/2009

participants Coronary Artery
Disease

Disease

Disease

participants
T. sample
Public Title StudyWHO* Scientific Title of StudyWHO*
size
A study to assess the safety and A prospective, single arm, open trial
efficacy of Fondaparinux in to assess the safety and efficacy of
unstable angina and non-ST Fondaparinux in patients with 40
elevation myocardial infarction unstable angina and non-ST elevation
compared to historical controls myocardial infarction compared to
AR1108888 : FondaparinUx FondaparinUx Trial with UFH
treated with Enoxaparin. historical controls treated with
Trial with UFH during during Revascularization in
Enoxaparin. 4000
Revascularization in Acute AR1108888: Acute Coronary
Coronary Syndromes Syndromes (FUTURA) A prospective
(FUTURA/OASIS 8) study evaluating the safety of two
A Phase II clinical trial to study Safety and Efficacy of TRC4186 in
regimens of adjunctive intravenous
the effects of TRC4186, an the treatment of stable heart failure
UFH during PCI in high risk patients 300
investigational new drug in associated with HbA1 ≥ 6.5% or type
with UA/NSTEMI initially treated
patients with stable heart failure 2"ADiabetes receiving
DOUBLE oral BLIND,
with subcutaneous fondaparinux and
associated with type 2 diabetes hypoglycaemic
RANDOMIZED, therapy (with or
MULTICENTRIC,
A Clinical Trial to Assess The referred for early coronary
mellitus receiving oral anti- without
PHASE-III additional insulin) as an add-
Effects of a Drug, BG9928, given angiographyTRIAL
(OASIS TO8) COMPARE
diabetic drug with or without on to conventional treatment
THE EFFICACY, TOLERABILITY, for NA
intravenously, in Subjects With
insulin. heart failure.
AND SAFETY OF TABLET
Acute Decompensated Heart
Failure (ADHF) and Reduced PRASUGREL WITH TABLET
A clinical trial to study the effects A Randomized, Double-Blind,
Kidney Function CLOPIDOGREL IN THE
of drug, Prasugrel in patients Placebo Controlled Multi- Center and
TREATMENT OF PATIENTS 200
with acute coronary syndrome. Parallel Group Study of the Safety,
WITH ACUTE CORONARY
Tolerability and Efficacy of YM150 in
SYNDROME"
A Multicenter, Randomized, Double-
combination with Standard
Study Evaluating Safety, Blind, Parallel Group, Active-
Treatment in Secondary Prevention
Tolerability and Efficacy of Controlled Study to Evaluate the
of Ischemic Vascular Events in 1264
YM150 in Subjects with Acute Efficacy and Safety of Both Aliskiren
Subjects with Acute Coronary
Coronary Syndromes Monotherapy and Aliskiren/Enalapril
Syndromes Acronym : RUBY ? 1
Combination Therapy Compared to
Efficacy and Safety of Aliskiren Enalapril Monotherapy, on
and Aliskiren/Enalapril Morbidity and Mortality in Patients
Combination on Morbi-Mortality With Chronic Heart Failure (NYHA
in Patients With Chronic Heart Class
A II - IV). randomised, double-
prospective,
Failure (ATMOSPHERE) blind, double dummy, comparative,
A Clinical Trial to Evaluate the A Phase 3, Randomized, Double-
Safety and Efficacy of Apixaban parallel assignment, multicentric
Blind, Evaluation of the Safety and
In Subjects with a Recent Acute clinical trial to compare the safety
Efficacy of Apixaban In Subjects with
Coronary Syndrome and efficacy of Prasugrel vs.
a Recent Acute Coronary Syndrome
Clopidogrel in patients with
A clinical trial to study the effects moderate-to-high-risk Acute
of two drugs, prasugrel and Coronary Syndromes who are to
clopidogrel in patients with acute 220
undergo Percutaneous Coronary
coronary syndrome who are to Intervention (PCI).
undergo percutaneous
intervention
A Phase 2, Double-Blind, Double-
Dummy, Randomized, Parallel Group
Dose Finding Study To Investigate
the Safety and Tolerability of YM150
A study Evaluating Safety and in Subjects with Non-Valvular Atrial
Tolerability of YM150 Compared Dose Finding, Safety and Efficacy of
Fibrillation and to Compare the
to Warfarin in Subjects with Monthly Subcutaneous
Safety and Tolerability with
atrial fibrillation. Canakinumab Administration for the
Warfarin. Acronym OPAL-2
Treatment of Hyperglycemia in
Dose Finding, Safety and Efficacy Metformin Monotherapy Treated
of Monthly Subcutaneous Type 2 Diabetic Patients: a
Canakinumab Administration in Randomized, Double-Blind, Placebo-
Metformin Monotherapy Treated Controlled, Multi-Center Study
Type 2 Diabetic Patients Post-marketing study of clinical
A study of the clinical experience experience
AN OPEN LABEL, of Lipicure
RANDOMIZED, 80®
with atorvastatin 80 mg in (atorvastatin 80 mg) in patients
PARALLEL with
GROUP,
patients with acute coronary acute coronary syndromes
PROSPECTIVE, Acronym:
MULTICENTRE
syndromes (heart attack ) Cure - ACS
CLINICAL TRIAL FOR
A clinical trial to study the effect EVALUATION OF EFFICACY
of standard treatment of heart AND SAFETY OF PRASUGREL IN
failure on plasma levels of Apelin COMPARISON WITH 50
Effect of Therapy on Plasma Apelin
in patients with heart failure. CLOPIDOGREL IN ACUTE
Levels
A in PatientsOpen-Label,
Randomized, of Heart Failure.
Active-
CORONARY SYNDROME (ACS)
CLINICAL TRIAL FOR Controlled, Parallel-Group,
PATIENTS UNDERGOING
EVALUATION OF EFFICACY Multicenter Study to Determine the
PERCUTANEOUS CORONARY 240
AND SAFETY OF Safety and Efficacy of Albiglutide
INTERVENTION (PCI) Acronym:
PRASUGREL IN Administered in Combination With
PRIVILEGE PCI
COMPARISON WITH Insulin Glargine as Compared with
A Study to Determine the Safety the Combination of Insulin Glargine
CLOPIDOGREL IN ACUTE A Comparison of Platelet Inhibition
and Efficacy of Albiglutide and Preprandial Lispro Insulin in
CORONARY SYNDROME Following a Prasugrel 60 mg or 500
Administered in Combination Subjects With Type 2 Diabetes
(ACS) PATIENTS Prasugrel 30 mg Loading Dose With
With Insulin Glargine. Mellitus.
UNDERGOING or Without Pretreatment With a
A PERCUTANEOUS
Study of Acute Coronary Clopidogrel Loading Dose in Acute
CORONARY
Syndrome INTERVENTION
Patients Coronary Syndrome Patients Who
(PCI). Are to Undergo Percutaneous
Coronary Intervention
A STUDY TO EVALUATE THE
A STUDY TO EVALUATE THE EFFECT OF EDIBLE OIL
EFFECT OF EDIBLE OIL IN (RBS8020) IN PATIENTS OF TYPE
PATIENTS OF TYPE II A Multicenter, Randomized, Double- 30
II DIABETES MELLITUS &
DIABETES MELLITUS & Blind, Placebo-Controlled Study to
HYPERTENSION
A Clinical Outcomes Study of
HYPERTENSION. Evaluate Cardiovascular Outcomes
Cardiovascular Outcomes Study Darapladib versus Placebo in
Following Treatment with Alogliptin
of Alogliptin in Subjects With Subjects Following Acute Coronary
in Addition to Standard of Care in 5400
Type 2 Diabetes and Acute Syndrome to Compare the Incidence
Subjects with Type 2 Diabetes and
Coronary Syndrome of Major Adverse Cardiovascular
Acute Coronary Syndrome.
(EXAMINE) Events (MACE). (Short title: The
The Stabilization Of pLaques GSK PHI112844: A Phase IIa,
Stabilization Of pLaques usIng
usIng Darapladib-Thrombolysis Randomized, Single-Blind, Placebo-
Darapladib-Thrombolysis In 11500
In Myocardial Infarction 52 Trial Controlled, Parallel-Group Study to
Myocardial Infarction 52 [SOLID-
(SOLID-TIMI 52) Evaluate the Safety,
TIMI 52] Trial)
Pharmacokinetics, and Efficacy of 28-
A Phase IIa, Randomized, Single- day Repeat Oral Doses of
Blind, Placebo-Controlled, GSK1278863A in anaemic pre-
Parallel-Group Study to Evaluate 140
dialysis and hemodialysis-dependent
the Safety, Pharmacokinetics, patients
and Efficacy of 28-day Repeat
Oral Doses of GSK1278863A in
anaemic pre-dialysis and
hemodialysis-dependent patients
Cardiovascular outcomes study to
evaluate the potential of aleglitazar to
A clinical trial to study reduction reduce cardiovascular risk in patients
of cardiovascular mortality and with a recent acute coronary
morbidity in Type 2 diabetes 600
syndrome (ACS) event and type 2
mellitus patients with a recent diabetes mellitus (T2D)
Acutecoronarysyndrome event
DOT-HF Trial - International DOT.HF Diagnostic Outcome Trial in
trial to determine the diagnostic Heart Failure
outcome in Heart Failure 2300
South Asian Systolic Heart SASHFR (South Asian Systolic Heart

Failure Registry (SASHFR) : Failure Registry) : A multi-center,
Registry to understand benefits nonrandomized, prospective study to 800-1000
of implantable device therapy collect data pertaining to the
known as cardiac demographic and cardiovascular
PANARM HF : A clinical registry PANARM HF -A prospective, multi-
resynchronization therapy (CRT) profiles, management strategies and
to understand the disease profiles center, non-interventional to collect
on patients with heart failure clinical outcomes of HF patients. 2000
of patients who suffer from cardiac (at the referring physician stage),
arrhythmias and/or heart failure data pertaining to the demographic,
and to understand the diagnosis cardiovascular and disease etiology
Cardiac rehabilitation and quality The effects of exercise based cardiac 28
and treatment pathway of these profiles of patients who have
of life in congestive heart failure rehabilitation on quality of life in
patients symptomatic cardiac arrhythmias
congestive heart failure
&/or left ventricular dysfunction with
or without symptoms of heart failure.
A Phase II clinical trial to study the Safety and Efficacy of TRC4186 in 300
effects of TRC4186, an the treatment of stable heart failure
investigational new drug in patients associated with HbA1 ≥ 6.5% or type
with stable heart failure associated 2 Diabetes receiving oral
with type 2 diabetes mellitus hypoglycaemic therapy (with or
A Clinical Trial to Assess The A Randomized, Double-Blind,
receiving oral anti-diabetic drug without additional insulin) as an add-
Effects of a Drug, BG9928, given Placebo-Controlled, Parallel-Group
with or without insulin. on to conventional treatment for
intravenously, in Subjects With Study to Assess The Effects of
heart failure.
Acute Decompensated Heart Intravenous BG9928 on Body Weight
Failure (ADHF) and Reduced in Subjects with Acute
Efficacy and Safety of Aliskiren A Multicenter, Randomized, Double-
Kidney Function Decompensated Heart Failure and
and Aliskiren/Enalapril Blind, Parallel Group, Active-
Renal Insufficiency
Combination on Morbi-Mortality Controlled Study to Evaluate the
in Patients With Chronic Heart Efficacy and Safety of Both Aliskiren
Failure (ATMOSPHERE) Monotherapy and Aliskiren/Enalapril
Effect of Vildagliptin on Left A Multi-Center, Randomized,
Combination Therapy Compared to
Ventricular Function in Patients Double-Blind, Placebo-Controlled
Enalapril Monotherapy, on
With Type 2 Diabetes and Clinical Trial to Evaluate the Effect
Morbidity and Mortality in Patients
Congestive Heart Failure of 52 Weeks Treatment With
With Chronic Heart Failure (NYHA
Vildagliptin on Left Ventricular
Class II - IV).
A clinical trial to study the effects Ventricular Septal Defect - 124
Function in Patients With Type 2
of propranolol (a beta blocking Propranolol for Heart Failure (VSD-
Diabetes and Congestive Heart
drug) in children with ventricular PHF Study)
Failure
septal defect and heart failure
Six Months Efficacy and Safety of A Multicenter, Randomized, Double-
Aliskiren Therapy on Top of Blind, Parallel Group, Placebo-
Standard Therapy, on Morbidity Controlled Study to Evaluate the 6
and Mortality in Patients With Months Efficacy and Safety of
Acute Decompensated Heart Aliskiren Therapy on Top of
Failure (ASTRONAUT) Standard Therapy, on Morbidity and
Mortality When Initiated Early After
Hospitalization for Acute
Decompensated Heart Failure
LCZ696 Compared to Valsartan in A Thirty Six-Week, Randomized, 290
Patients With Chronic Heart Double-Blind, Multi-Center, Parallel
Failure and Preserved Left- Group, Active Controlled Study to
Ventricular Ejection Fraction Evaluate the Efficacy, Safety and
Tolerability of LCZ696 Compared to
A clinical study to evaluate Adherent Monitoring of Congestive 40
Valsartan in Patients With Chronic
performance of a non-invasive Heart Failure during Therapy for
Heart Failure and Preserved Left-
study device to monitor patients Excess Fluid (ACUTE) Study
Ventricular Ejection Fraction
fluid status in congestive heart
failure.
A comparative evaluation of A comparative, single blind, parallel 200
efficacy, safety & tolerability of group, non-crossover, multi-centric
Carvedilol Phosphate Extended trial of Carvedilol Phosphate
Release Capsules 80 mg (Test Extended Release Capsules 80 mg
Drug), with Carvedilol Phosphate (Test Drug), with Carvedilol
A clinical trial to study the effect of Effect of Therapy on Plasma Apelin 50
Extended Release Capsules 80 mg Phosphate Extended Release
standard treatment of heart failure Levels in Patients of Heart Failure.
(Reference Drug), in-patients Capsules 80 mg (Reference Drug), in-
on plasma levels of Apelin in
suffering from mild to severe heart patients suffering from mild to severe
patients with heart failure.
failure of ischemic or heart failure of ischemic or
cardiomyopathic
This origin. the
Study Will Evaluate cardiomyopathic
A origin.
Multicenter, Randomized, Double- 7980
Efficacy and Safety of LCZ696 blind, Parallel Group, Active-
Compared to Enalapril on controlled Study to Evaluate the
Morbidity and Mortality of Efficacy and Safety of LCZ696
Patients With Chronic Heart Compared to Enalapril on Morbidity
A clinical trial with ivabradine in Effects of ivabradine in patients with 11330
Failure (PARADIGM-HF) and Mortality in Patients With
patients with stable coronary stable coronary artery disease
Chronic Heart Failure and Reduced
artery disease without clinical heart failure. A
Ejection Fraction
randomised double-blind placebo-
controlled international multicentre
A clinical trial to study the efficacy Evaluation of efficacy and safety of 102
study. Study assessInG the morbi-
and safety of metoprolol in heart metoprolol in patients having heart
mortality beNefits of the If inhibitor
failure with normal ejection failure with normal ejection fraction:
ivabradine in patients with coronary
fraction a Randomised, Double-Blind,
arterY disease ( SIGNIFY)
Placebo-Controlled Trial
A clinical trial comparing A Randomized, double-blind,
bronchodilator effects of two crossover, non-inferiority study
drugs,Tiotropium Bromide and comparing bronchodilator effects of
Formoterol Fumarate each over 24 single dose of 18 mcgg of Tiotropium
hours in subjects with Asthma. Bromide and two doses of 12 mcg of
A study evaluating the therapeutic A study evaluating the therapeutic
Formoterol Fumarate each over 24
potential of low dose potential of low dose Roxithromycin
hours in subjects with moderate to
Roxithromycin therapy in patients therapy in patients of stable
severe asthma.
of stable bronchial asthma. bronchial asthma.
A clinical trial to study the lung A gamma scintigraphy study to 10
deposition of a pressurized metered determine the lung deposition of
dose inhaler (pMDI)in patients inhaled aerosolized radiolabeled
with COPD and Asthma budesonide/formoterol(200/6mcg)in
patients with COPD and Asthma
A study to assess the safety and A prospective, single arm, open trial 40
(Phase IV study)
unstable angina and non-ST Fondaparinux in patients with
Enoxaparin.
A study to assess the safety and A prospective, single arm, open trial 40
unstable angina and non-ST Fondaparinux in patients with
XIENCE V India: XIENCE V XIENCE V Everolimus Eluting
Everolimus Eluting Coronary Stent Coronary Stent System (EECSS)
Enoxaparin.
System (EECSS) India Post- India Post-Marketing Registry
Marketing Registry
Intek Apollo Paclitaxel Eluting Clinical success and safety of Intek 100
coronary stent study Apollo coronary drug eluting stent
with paclitaxel release in patients
with de novo lesion
Series III Run-In Trial: Random Series III Run-In Trial: A 360
comparison of Supralimus(R) with randomized comparison of the
Xience V(TM) in the treatment of Supralimus(R) stent with the Xience
patients suffering from new V(TM) stent in the treatment of
congenital atherosclerosis of
E-SERIES Registry: Supralimus(R) and
patients with de novo native coronary
E-SERIES Registry: A Prospective and 3000
coronary arteries
Supralimus-Core(TM) Cardiac Stents for artery lesions
Retrospective, Multinational Investigation
the Treatment of Coronary Artery of the Supralimus(R) and Supralimus-
Blockage. Core(TM) Sirolimus-Eluting Stents for the
Treatment of Unselected Patients with
Coronary Lesions in the Real-World
Clinical Practice
Esti trial total Sites
Phase Site 1
duration no
Department of cardiology,
Phase 3 3 Months 1
CMC hospital
Phase
14 Banker's Heart Institute
3/Phase 4
Spandan Heart Institute

Phase 2 2 Years 6
and Research Center
SAL Hospital & Medical

Phase 3 NA 11
Institute
Cooper Hospital,
Phase 3 5 Months 4 Vileparle(W), Mumbai,
nitinmr64@yahoo.com
Phase 2 21 Months 16 The Heart Care Clinic
Phase 3 24 PRS Hospital
Tagore Heart Care and

Phase 3 Years 30
Research Centre,
G. B. Pant Hospital &

Phase 3 12 Months 14 Maulana Azad Medial
College
Deenanath Mangeshkar
Phase 2 Months 15 Hospital & Research
Centre
Phase Amrita Institute of

12
2/Phase 3 Medical Sciences
Escorts Heart Institute

Phase 4 Months 9 and Medical Research
Center
Room No. 4046D,

Not
2 Years 2 Department of
Applicable
Pharmacology, A.I.I.M.S.
B.M. Birla Heart Research

Phase 3 12
Centre
Phase 3 35 Months 12 ACEER
Narayana Hrudayalaya
5
Institute of Medicine
Phase 3 5 Months 1 IRL Research Centre
Phase 3 4.75 Years 40 KEM Hospital
Nizam's Institute of
Phase 3 5 Years 27
Medical Sciences
Phase 2 12 Months 7 BYL Nair Hospitak

Phase 3 4 Years 40 Care hospitals
Phase
5 Years 3 Dr. Ajay Naik
3/Phase 4
Phase 4 5.5 Years 11 The Heart Care Clinic
Not
2 Years 8
Applicable
C-4/3 Vasant Vihar
Not 1 Years 1 Department of
Applicable physiotherapy
Phase 2 2 Years 6 Spandan Heart Institute

and Research Center
Phase 3 Years 11 SAL Hospital & Medical

Institute
Phase 3 Years 24 Metro Multispeciality

Hospital
Phase 4 Months 11 FORTIS FLT. LT.

RAJAN DHALL
HOSPITAL
Phase 2 Years 1 AIIMS

3/Phase 4
Phase 3 18 MGM Medical College &

M.Y Hospital
Phase 2 1 Years 9 S. R. Kalla Memorial
Gastro & General
Hospital
Not 12 Months 1 Escorts Heart Institute

Applicable and Research Center,
Okhla Road, New Delhi
(India)-110 025
Phase 3 3 Months 2 Apex Superspeciality
Hospital
Not 2 Years 2 Room No. 4046D,

Applicable Department of
Pharmacology, A.I.I.M.S.
Phase 3 43 Months 30 Choithram Hospital &

Research Centre
Phase 3 2.5-5 Years 9 Escorts Heart Institute

and Research Centre
Phase 2 2 Years 1 PGIMER
Phase 3 1 Years 1 Chest Research

Foundation
Phase 4 Months 1 Chest Research

Foundation
Phase 4 45 Days 1 Institute of Nuclear

Medicine & Allied
Sciences (INMAS)
Phase 3 3 Months 1 Department of cardiology,

CMC hospital
Phase 3 3 Months 1 Department of cardiology,
CMC hospital
Phase 4 Years 18 Escorts Heart Institute &

Research Centre
Phase 3 1 Years 6 Meenakshi Mission

Hospital & Research
Centre
Phase 4 Years 15 PRS Hospital
Phase 4 2 Years 1 Shri B.D. Mehta Mahavir Heart

Institute
Site 2 Site 3 Site 4
Avanti Institute of Spandan Heart Institute &

Heart & General Hospital
Cardiology Research Centre
Avanti Institute of
CARE Hospital Shri Ram Cardiac Center
Cardiology
narayana Hrudayalaya
5th Floor, Sir Ganga Ram Institute of
Hospital Cardiovascular Diseases
Sciences
K.E.M.Hospital & Seth

Clinic Smt. N H L Muni. Medical
G.S. Medical
,Bhavnagar,Rajivoza59@h College,Ahmedabad,Rajp
College,Mumbai,pkirtic@
otmail.com urvi@yahoo.com
yahoo.in
Department of Cardiology,
Life Care Institute of Total CardioVascular
Prime Hospital
Medical Science and Solutions Pvt. Ltd
Research
Meenakshi Mission
Metro Multispeciality Dharma Vira Heart
Hospital and Research
Hospital Centre
Centre
S.R.Kalla Memorial
Shri Krishna Hrudayalaya Cardiac Care &
Gastro & General
& Critical Care Centre Counseling Center
Hospital
M S Ramaiah Narayana Wockhardt Heart

PGI
Hrudalaya, Hospitals
Healing Touch
Bollineni Ramanaiah Meenakshi Mission Angiography & Cardiac
Memorial Hospital (P) Hospital & Research Surgery Centre, Gupte
Limited Centre Cardiac Care Centre and
Hospital
Bangalore Diabetes Madras Diabetes Research Health and Research

Hospital Foundation Centre
Life Care Institute of

Grant Medical Foundation Medical Science & CARE Hospital
Research Centre
Cardiology OPD,

Ruby Hall Clinic Medical Science & Fortis Hospital
Research Centre
Bangalore Diabetes Medisys Clinisearch India Kasturba Medical College

Hospital Pvt Ltd Hospital
Christian Medical College All India Institute of

Care Hospital
and Hospital Medicine
Escorts Heart Institute Shatabdi Superspeciality

Sterling Hospital
and Research Centre Hospital
Department of Medicine,
Hospital & Research Institute of
M.G.M. Medical College
Center, Dept. of Cardiovascular Diseases,
and M.Y. Hospital,
Cardiology
Pondicherry Inst of
Osmania General Hospital King George Hospital
Medical Sciences
Mediciti Hospital Medwin Hospitals
Hospital
Escorts Heart Institute &

TCVS
Research Centre

CARE Hospital Madras Medical Mission
Research Center
Fortis Escorts Hospital

Escort Heart & Research
Institute Heart Care Clinic
Avanti Institute of CARE Hospital Shri Ram Cardiac Center

Cardiology
narayana Hrudayalaya 5th Floor, Sir Ganga Ram Institute of

Institute of Medical Hospital Cardiovascular Diseases
Sciences
Meenakshi Mission Dharma Vira Heart Kasturba Hospital

Hospital and Research Centre
Centre
DAYANAND MEDICAL S.R. KALLA KING GEORGE

COLLEGE AND MEMORIAL HOSPITAL HOSPITAL ANDHRA
HOSPITAL MEDICAL COLLEGE
St. John's Medical College G Kuppuswamy Naidu Narayana Hrudayalaya

Hospital Memorial Hospital Institute of Medical
Sciences
Mediciti Hospitals, Dharma Vira Heart Monilek Hospital &
Shree Venkatesh Hospital

and Polyclinic
Cardiology OPD,
Bankers Heart Institute Health And Research Care Hospital

Center
TCVS Pvt Ltd Life Care Institute of Spandan Heart Institute

Medical Science and
Research
Madras Medical Mission Holy Family Hospital Krishna Heart Institute
Madras Medical Mission Life Care Institute of Wockhardt Heart Hospital

Medical Sciences &
Research Centre
Apollo Hospital Shri.Jayadeva Institute of Madras Medical Mission

Cardiology
Sanjay Gandhi Post

Max Devki Devi Heart and
Graduate Institute Of Sir Ganga Ram Hospital,
Vascular Institute,
Medical Sciences
Amrita Institute of
Hospital and Research
Medical Sciences
Centre
Christian medical College Delhi Heart and Lung WestFort Hi-Tech

and Hospital Institute Hospital Ltd
A. J. Hospital and Dharma Vira Heart

CARE Hopsitals
Research Centre Centre
Health and Research

Kasturba Hospital Mediciti Hospitals
Centre
M.S Ramaih Memorial

The Heart Care Clinic Sir Ganga Ram Hospital
Hospital
Life Care Institute of Grant Medical

Kovai Medical Centre &
Medical Sciences & Foundation, Ruby Hall
Hospital Limited,
Research, Clinic,
M. S. Ramaiah Memorial
Yasoda Hospital Sanjay Gandhi PGIMS
Hospital
Jnana Sanjeevini Medical Nizam?s institute of Pitale Diabetes &

Center Medical Sciences Hormone centre
Department of Cardiology, B.M. Birla Heart Research Kokilaben Dhirubhai

PRS Hospital Centre Ambani Hospital
Shree Saibaba Heart

Institute & Research Hridayam Heart Care V.S. General Hospital
Centre
Madras Diabetes Research Gokula Metropolis Manipal AcuNova KH

Foundation Clinical Research Center Clinical Research Center,
Sir Ganga Ram Hospital
Lifecare Institute of
Dande Diabetes and Heart
Medical Sciences and Bhatia Hospital
Care Centre
Research
Fortis Escorts Hospital, (A

Unit of Escorts Heart and Bankers Heart Institute
Research Centre
Super Specialty Limited)
Rangdore Memorial MAMC - Lok Nayak

Manipal Hospital
Hospital Hospital
KLES Dr.Prabhakar Gandhi's Research Instride Hospital &
KORE hospital Institute research centre
Indraprastha Apollo
Glenmark Cardiac Center Frontier Lifeline
Hospital
Fortis Hospital, Mohali

Escorts Hospital &
Research Center Escorts Hospital
Deenanath Mangeshkar Amrita Institute of

Hospital and Research Medical Sciences
Centre
Christian medical College Delhi Heart and Lung WestFort Hi-Tech

and Hospital Institute Hospital Ltd
Health and Research Mediciti Hospitals St. John's Medical College

Centre and Hospital
HEALTH AND LIFE CARE INSTITUTE PITALE DIABETES &

RESEARCH CENTRE OF MEDICAL SCIENCE HORMONE CENTRE
& RESEARCH
Omega Hospital Deenanath Mangeshkar Escorts Heart Institute

Hospital and Research and Research Centre
Centre
Kasturba Hospital Wockhardt Heart Hospital Crescent Hospital & Heart
Centre
Mediciti Hospital Omega Hospital Shri Krishna Hrudayalaya

& Critical Care Centre
Ruby Hall Clinic PSG Hospitals Holy Family Hospital

Poona Hospital And SAL Hospital And Lissie Hospital
Research Centre Medical Institute
Grant Medical Zynova Heart Hospital

Foundation, Ruby Hall
Clinic
Jaslok Hospital & Life Care Institute KEM Hospital

Research Centre
St. Johns Medical College Poona Hospital &

Holy Family Hospital
& Hospital Research Centre
St. John's Medical College MGM Medical College

S.P. Medical College
Hospital and MY Hospital
Institute of Cresent Hospital and

Nanjappa Hospital
Cardiovascular Diseases Heart Centre
S. R. Kalla Memorial
St. John's Medical College
Gastro & General Holy Family Hospital
and Hospital
Hospital
Baroda Heart Institute & M.V. Hospital and SP Medical College & AG
Research Centre Research Center Hospitals,
Dr. Ramesh Cardiac and Institute of Post Graduate

KEM Hospital & Seth GS
Multispeciality Hospital Medical Education &
Medical College,
Ltd., Research,
Avanti Institute of Bhagwan Mahaveer Jain
Apollo Gleneagles
Cardiology Hear Centre
Samatvam: Endocrinology S.R Kalla Memorial Gokula Metropolis

Diabetes Centre Hospital Clinical Research Centre
Fortis Hospital Apollo Hospital
Kamalnayan Bajaj
V.S. General Hospital Sterling Hospital
Hospital
Diabetes Care and CARE Foundation, CARE

KEM Hospital
Research Centre, Hospital
Deenanath Mangeshkar Maulana Azad Medical

ShreeKrishna Hospital
Hospital and Research College and Guru Nanak
and Heart care centre
Centre Eye Centre
Gurunanak CARE
Ruby Hall Clinic CARE Hospital
Hospital
CRESCENT HOSPITAL
Health and Research
KEM Hospitals Belgaum Diabetes Centre
Centre
Fortis Hospital Medanta- The Medicity Asian Heart Institute
Indraprastha Apollo Hosp
St. John's Medical College S.P. Medical College MGM Medical College
Hospital and MY Hospital
S. R. Kalla Memorial Holy Family Hospital Indraprastha Apollo

Gastro & General Hospitals
Hospital
Jnana Sanjeevini Medical Bankers Heart Institute, Krishna Institute of

Center Medical Sciences
Bankers Heart Institute Arneja Heart Institute Crescent Hospital & Heart
Centre
Osmania Medical College L.T.M.M College &
Hospital
Bisne Heart Hospital Sri Gokulam Medical Ruby Hall Clinic

College & Research
Foundation
Artemis Health Institute Max Devki Devi Heart and

Vascular Institute
Apollo Hospital Christian Medical College Dayanand Medical College
& Hospital
B.M.Birla Heart Research Ruby Hall Clinic Escorts Heart Institute &
Center Research Centre
Krishna Heart & Super Krishna Institute of

Sterling Hospital,
Specialty Institute Medical Sciences
3-MM II, Panchkuian

Road
Sangini Hospital,
Sri Venkateswara Institute J.S.S. Hospital and
Neonatal, Padiatric &
of Medical Sciences Medical College
Adult Intensive Care Units
Indraprastha Apollo Dr. Kamakshi Memorial

CRESCENT HOSPITAL
Hospitals Hospital
TCVS Pvt. Ltd Heart & General Hospital Apollo Hospitals
Apollo Gleneagles All India Institute of

Care Hospital,
Hospitals Ltd Medical Sciences,
Poona Medical Research Krishna Heart & St. John's Medical College
Foundation Superspeciality Institute Dept. of cardiology
Diabetes Thyroid
King George Hospital Hormone Research
Institute
Krishna Institute of
Sterling Hospital
Medical Sciences
Dande Diabetes & Heart M.V.Hospital for diabetes

Care Centre, Maternity & and Diabetic Research
Nursing Home, Centre
St. Johns Medical College

Care Hospital Bankers Heart Institute
and Hospital
The Heart Care Clinic Fortis Hospital Mediciti Hospitals

Bangalore Endocrinology
KMC Hospital St Johns Medical College and Diabetes Research
centre
Christian Medical College
Hospital & Research
Centre
Dr. Kamakshi Memorial CRESCENT HOSPITAL SHRIKRISHNA

Hospital HRUDAYALAYA AND
CRITICAL CARE
Omega Hospital
KEM Hospital Poona Hospital and Amrita Institute of

Research Centre Medical Sciences
Heart First Cardiac and Nimit Matra Hospital Shree Sai Baba Heart
Vascular Clinic Institute and Research
Center
Escorts Heart & Fortis Hospital Max Devki Devi Heart &
Superspeciality Institute Vascular Institute
Ltd.
Kailash Health Care Sanjay Gandhi Post Max Devki Devi Heart and
Limited Graduate Institute of Vascular Institute
Medical Sciences
The Heart Care Institute,
Aditya Hospital & Critical

Radiance Hospital Arneja Heart Institute
Care Unit
SHRIKRISHNA
ARNEJA HEART BISNE HOSPITAL PVT
HRUDAYALAYA AND
INSTITUTE, LTD
CRITICAL CARE
Grant Medical
Monilek Hospital And Foundation, Ruby Hall
Hospital and research
Research Centre Clinic, 40, Sasoon Road,
center,
Pune - 411001
Care Hospital,
Heart Care Clinic Narayana Hrudayalaya
Meenakshi Mission
Sir Ganga Ram Hospital Hospital and Research Omega Hospital Pvt. Ltd.
Centre
Dept. of Cardiology,
Apollo Hospitals
Fortis Escorts Hopsital Dharma Vira Heart
International Ltd
Centre,
Poona Hospital and Res
JSS Hospital Ruby Hall Clinic
Centre
ARNEJA HEART BISNE HOSPITAL PVT AVANTI INSTITUTE OF

INSTITUTE, LTD CARDIOLOGY PVT.
LTD
Mediciti Hospitals Krishna Institute of Frontier Lifeline Pvt Ltd

Medical Sciences
Metro Multispeciality Dharam Vira Heart Bhanubhai & Madhuben
Hospital Centre Patel Cardiac Centre
Jehangir Hospital CARE Hospital Heart & General Hospital
All India Institute of Escorts Heart Institute &

Medical Sciences Research Centre
AVANTI INSTITUTE OF
CARDIOLOGY PVT. RUBY HALL CLINIC K.E.M HOSPITAL,
LTD
Escorts Heart Institute

Lifecare Institute of "Patiala Heart Institute, 2-
and Research Center,
Medical Sciences & Jagdish Marg, Patiala-147
Okhla Road, New Delhi -
Research, 001 (Punjab) India
110025
S R Kalla Memorial
Dayanand Medical College
Osmania Medical College Gastro and General
and Hospital
Hospital
Cardiology Department,
Krishna Institute of
Sterling Hospital Sadbhavna Medical &
Medical Sciences,
Heart Institute
Narayana Hrudayalaya
Lakeshore Hospital and
BGS Global Hospital Institute of medical
Res Ctr
sciences
RUBY HALL CLINIC K.E.M HOSPITAL, DEENANATH

MANGESHKAR
HOSPITAL &
RESEARCH CENTRE
Sri Jayadeva Institue of Kovai Medical Center and

Cardiology Hospital Limited
Bhanubhai & Madhuben Deep Heat Centre Choithram Hospital &
Patel Cardiac Centre Research Centre
Escorts Heart Institute & Krishna Institute of
Research Centre Medical Sciences
DEENANATH NARAYANA
KOVAI MEDICAL
MANGESHKAR HRUDAYALAYA
CENTER AND
HOSPITAL & INSTITUTE OF
HOSPITAL LIMITED
RESEARCH CENTRE MEDICAL SCIENCES
Narayana Hrudayalaya,
Vikram Hospital & Heart
258/A- Bommasandra
Care, #46, Vivekananda G. Kuppuswamy Naidu
Industrial Area, Anekal
Road, Yadavagiri, Memorial Hospital,
Taluk, Bangalore-560 099
Mysore-570020 Karnataka
Karnataka
Christian Medical College West Fort Hi-tech
Kovai Medical Centre
and Hospital Hospital
Medanta -The Medicity,

Apollo Hospitals Fortis Hospital,
Medanta Heart Institute,
Global hospital & health Jnana Sanjeevini Med
Asian Heart Institute
city Centre
NARAYANA KOVAI MEDICAL Yashoda Hospital

HRUDAYALAYA CENTER AND
INSTITUTE OF HOSPITAL LIMITED
MEDICAL SCIENCES
JSS Medical College Life Care institiute of Kalcadiya Hospital
Medical Science
&Research
Site 22 site 23 Site 24
Sanjivani Super Speciality

Yashoda Hospital
Hostpital,
Holy Family Hospital, St. Mediciti Hospitals, 5-9-22,

Nanjappa Hospital, 660,
Andrew's Road, Bandra Secretriat Road,
Kuvempu Road, Shimoga-
(West) Mumbai-400050 Hyderabad- 500063
577201 Karnataka
Maharashtra Andhra Pradesh
Ramesh Cardiac and
Multi Speciality Hospital Holy Family Hospital Yashoda group of Hospital
Ltd.
Sanjay Gandhi CARE Hospital (Visakha

Fortis Flt. Lt. Rajan Dhall
Postgraduate Institute of Hospitals & Diagnostics
Hospital
Medical Sciences Ltd.) A.S. Raja Complex
Amrita Institute of Med MSRamaiah Narayana Mahavir Hospital and
Sci Hurdyalaya Research Centre
Sanjivani Super Speciality PRS Hospital

Hostpital,
Indus Hospital JSS Medical College Fortis Malar Hospital
Fortis Escorts Avanti Institute of

Dr Ramesh Cardiac & HospitalJLN Marg, Cardiology, 5- Abhyankar
Multispeciality Hosp. Ltd., Malviya NagarJaipur-302 Road, Dhantoli, Nagpur-
017Rajasthan 440012 Maharashtra
Narayanan Hrudayalaya
Institute of Medical Care Hospital Mediciti Hospital
Sciences
Fortis Escorts Hospital

and Research Centre
Lotus diagnostic Centre Artemis Health Institute
Medical Sciences
Osmania Medical College Little Flower Hospital And Wockhardt Heart Hospital
Research Centre
"Hope Specialty Hospital,

Shri Sai Baba Heart
200- W K Road, Meerut ?
Institute & Research
250001 Uttar Pradesh,
Centre,
India.
P S Medical College and
P R S Hospital Frontier Lifeline Hospital
Shree Krishna Hospital
Yashoda Super Speciality Krishna Institute of
The Heart Care Clinic
Hospitals Medical Sciences
Vijan Cardiac & Critical St. Isabels Hospital
Care Centre
Shree Saibaba Heart
Tagore Heart Care and
Medwin Hospitals Institute and Research
Research Centre
Centre
Endocrinology Diabetes Inst of Post Grad Med Ed City Diagnostics WE-
Center Res LINK SMO
Trial UTRN.WHO CTRI No.and Date Status of Last

No. TrialWHO Verified
on11/18/2008
Trial 1 TEMP UTRN 050440745- CTRI/2008/091/000248, Closed to
11112008346614 18-11-2008 recruitment of
participants
Trial 2 TEMP UTRN 041851255- CTRI/2008/091/000001, Open to 8/22/2008

0201200863215 22-08-2008 recruitment
Trial 3 TEMP UTRN 020846127- CTRI/2008/091/000010, Not yet 1/25/2008

2001200876203 25-01-2008 recruiting
Trial 4 TEMP UTRN 051429058- CTRI/2008/091/000014, Completed 3/27/2008

3101200880234 27-03-2008

11042008115187 24-04-2008 recruitment

22042008122327 30-04-2008 recruiting

25042008129327 30-04-2008 recruiting
Trial 8 TEMP UTRN 080401529- CTRI/2008/091/000070, Closed to 6/30/2008

23052008146368 30-06-2008 recruitment of
participants
26052008147187 15-07-2008

28052008150129 09-06-2008 recruitment

09062008173164 19-06-2008 recruitment

30062008188406 21-07-2008

10072008203420 05-11-2008

21092008274557 25-09-2008 recruitment

1609200826427 03-11-2008 recruitment of
participants

2909200828648 11-09-2009 recruitment
08102008298602 16-06-2009

13102008303620 17-11-2008 recruitment

29102008323509 12-01-2009
Trial 20 TEMP UTRN 024937708- CTRI/2008/091/000254, Terminated 11/28/2008

19112008352605 28-11-2008

08122008374753 12-12-2008 recruitment of
participants

15122008386609 28-01-2010

19122008397753 22-12-2008

19122008398753 22-12-2008

07012009424529 03-02-2009
100320095101078 03-09-2009

28012009460856 13-10-2009 recruitment

02042009581207 09-06-2010

13022009485959 24-09-2009

230220094951008 04-03-2009 recruitment
Trial 31 TEMP UTRN 035024123- CTRI/2009/091/000098, Terminated 29-05-2009

130320095181087 29-05-2009

190320095241079 04-05-2009 recruitment
Trial 33 TEMP UTRN 045133155- CTRI/2009/091/000119, Open to 15-04-2009

25032009539178 15-04-2009 recruitment
Trial 34 TEMP UTRN 020607659- CTRI/2009/091/000123, Closed to 16-04-2009

260320095431032 16-04-2009 recruitment
follow up
continuing &
closed to
recruitment
follow up
complete fully
26032009545874 31-03-2009 recruitment of
participants

220420096201211 15-05-2009 recruitment

150520097221180 27-05-2009 recruitment

150520097241180 25-05-2009 recruitment

240420096301078 04-05-2009 recruitment of
participants

270420096371165 29-05-2009 recruitment of
participants

150620098211532 10-07-2009 recruitment

200620098661475 06-07-2009 recruitment of
participants

22062009869178 20-08-2009 recruitment of
participants
0108200910731078 11-08-2009 recruitment

300620099461444 21-07-2009 recruitment of
participants

030720099641332 15-07-2009 recruitment of
participants

060720099761734 23-07-2009 recruitment of
participants
Trial 48 TEMP UTRN 110034575- CTRI/2009/091/000536, Terminated 17-08-2009

09072009999235 17-08-2009

080720099951735 12-08-2009

0707200999036 09-09-2009 recruitment

08072009991744 27-07-2009 recruitment

090720091000859 09-12-2009

1307200910091643 03-12-2009 recruitment
1407200910151032 30-07-2009 recruitment

290720091062602 18-08-2009 recruitment

150720091023832 03-09-2009
Trial 57 TEMP UTRN 114055429- CTRI/2009/091/000590, Not yet 29-01-2010

2507200910541835 29-01-2010 recruiting

1008200910971032 13-08-2009 recruitment

110820091102602 24-09-2009 recruitment
Trial 60 TEMP UTRN 073509822- CTRI/2009/091/000656, Completed 22-09-2009

160820091124832 22-09-2009
Trial 61
Trial 62
Trial 63
Trial 64
Trial 65
Trial 66
Trial 67
Trial 68
Trial 69
Trial 70
Trial 71
Trial 72
Trial 73
Trial 74
Trial 75
Trial 76
Trial 77
Trial 78
Trial 79
Trial 80
Trial 81
Trial 82
Last Speciality- Public Title Scientific Title of T. Phase
Updated Subspeciali StudyWHO* StudyWHO* sample
on9/14/2009 ty To compare the efficacy A Randomized, Two
size
1 Phase 4
Diabetic
and safety of a new Arm, Open Label,
formulation of Comparative, single
telmisartan with the centre study to evaluate
currently available efficacy and safety of 2
formulation in the generic formulations of
8/21/2008 Diabetic ALiskiren
management TrialofIn Type 2 A randomized,
telmisartan double-
in patients 8600 Phase 3
diabetes Using
patients with type 2 blind, placebo-
with type 2 diabetes
cardiorenal
diabetes and Disease controlled, parallelgroup
and hypertension
Endpoints
hypertension study to determine
whether, in patients
with type 2 diabetes at
1/24/2008 Diabetic A clinical trial to study Prevalence
high risk forof Adverse 200 Phase of Trial*
the existence of Neural Tension and
cardiovascular in
reduced nerve mobility Geriatric Population
renal events, aliskiren,
in old age individuals, With
on top and
of Without
conventional
comparing diabetic and Diabetes
treatment, Mellitus-
reducesStudy
non-diabetic subjects of Responses Elicited
cardiovascular and or
7/17/2009 Diabetic Effect of liraglutide or Effect of liraglutide Phase 3
and to study the effects During
renal Neurodynamic
morbidity and
glimepiride added to glimepiride added to
of nerve mobilization (a Testing
mortality and Effects of
Acronym:
metformin on blood metformin on glycaemic
physiotherapy Neural
ALTITIUDEMobilization
glucose control in control in subjects with
treatment method)
subjects with type 2 type 2 diabetes
diabetes
7/1/2008 Diabetic A Glycemic Control A Randomized, Double- 500 Phase 3
Evaluation of Blind, Parallel-Group,
Glimepiride versus Multicenter,
Rimonabant on Top of Multinational Study to
Metformin in Type 2 Assess Glycemic Control
Diabetes with Rimonabant in
Comparison with
1/1/2007 Diabetic A clinical trial to study A Proof of Concept 180 Phase 2
Glimepiride over 1 Year
the effects of 2 prospective, double-
in Overweight/Obese
Ayurvedic formulations, blind, placebo
Type 2 Diabetic Patients
containing controlled, comparative,
Not Adequately
Ashwagandha, Brahmi randomized, parallel
Controlled with
and Amalaki on the group, multi-centric
Metformin
physical and emotional clinical study to
well-being of elderly evaluate short-term
1/1/2007 Diabetic A clinical trial to study
subjects. A ProofofofPHP-Ageing
effect Concept on 60 Phase 2
safety and activity of prospective,
the physical and double
Ayurvedic formulation blind, placebo
emotional well-being of
containing controlled, randomized,
elderly subjects.
Ashwagandha and multi-¬centric study to
Haridra in patients with evaluate the safety and
Type 2 Diabetes activity of PHP-Diabetes
5/21/2010 Diabetic A clinicalreceiving
mellitus trial to assess
oral An open-label,
in patients with Type 2 200 Phase 4
the frequencyagents
anti-diabetic of "low prospective study to
Diabetes mellitus
sugar" in the mother observe
receivingthe oralincidence
anti- of
with elevated sugars hypoglycemia
diabetic agentswith
(during pregnancy) insulin aspart in
using insulin aspart. pregnant women with
any degree of
hyperglycemia. HIP -
INDIA study i.e.
Hyperglycemia In
Pregnancy- India study.
7/2/2010 Diabetic A clinical trial to study A randomized, double- Phase 3
the efficacy and safety blind, placebo-
of AVE0010 in patients controlled, parallel-
with type 2 diabetes not group, multicenter 12-
treated with antidiabetic week study assessing
agents the efficacy and safety
6/3/2008 Diabetic Role of a probiotic, Small intestine
of AVE0010 bacterial
in patients 60 Phase 2/Phase 3
VSL#3, in patients with overgrowth and role of
with type 2 diabetes not
nonalcoholic fatty liver probiotic,
treated with VSL#3 in
antidiabetic
disease. patients
agents with
nonalcoholic fatty liver
disease
3/5/2010 Diabetic Vascular Endothelial A randomized, double Phase 2/Phase 3
Growth Factor (VEGF) masked, active
Trap-Eye: Investigation controlled, phase 3
of Efficacy and Safety in study of the efficacy,
Wet Age-Related safety, and tolerability
Macular Degeneration of repeated doses of
(AMD) (VIEW 2) intravitreal VEGF Trap-
11/21/2009 Diabetic A clinical trial to study A
Eyerandomized
in subjectsdouble-
with 42 Phase 4
the effect of blind placebo-controlled
neovascular age-related
atorvastatin on prospective evaluation
macular degeneration
pancreatic beta-cell of the effect of
(AMD)
function & insulin atorvastatin on
resistence in patients pancreatic beta-cell
11/4/2008 Diabetic Effect of high
with type dose
2 diabetes A randomised,
function double-
and insulin 40 Phase 1/Phase 2
vitamin
mellitus B1 on early blind, placebo-
resistance in type-2
stage kidney disease in controlled study to
diabetes mellitus
type 2 diabetes assess
patients: if high dose
A pilot study
thiamine therapy of
type diabetic patients
9/9/2009 Diabetic Evidence of Good A Prospective, Phase 4
with microalbuminuria
Glycemic control in Monocentric, Open
decreases the urinary
Conceptions through labelled, Multiple arm
excretion of albumin
Assisted Reproduction study on the influence
Acronym: THIAMA
Technology [EGG CART of strict periconception
Study] glycemic control in
women with various
degrees of glucose
intolerance in the
7/27/2009 Diabetic A clinical study to Effects
setting of Atorvastatin
conceptions Not Applicable
assess the effects of and Pioglitazone
through Assisted on
two drugs, atorvastatin Endothelial
Reproduction Dysfunction
and pioglitazone in in non-diabetic patients
Technology
patients of high blood with hypertension or
pressure or angina, but stable angina
9/2/2009 Diabetic Pilot Study Targeting REsearching Coronary 500 Phase 3
without diabetes
Normal Glucose in REduction by
Patients with Acute Appropriately Targeting
Myocardial Infarction Euglycemia ( Pilot
through appropriate use Study): An
of insulin therapy. International
Multicentre Randomized
Controlled Trial of
Intensive Insulin
Therapy Targeting
Normoglycemia In
Acute Myocardial
Infarction: the
RECREATE (REsearching
Coronary REduction by
Appropriately Targeting
Euglycemia) Pilot Study
6/16/2009 Diabetic Vildagliptin Compared A multicenter, double- Phase 3
to Gliclazide in blind, randomized,
Combination With active controlled study
Metformin in Patients to compare the effect of
With Type 2 Diabetes 52 weeks treatment
with LAF237 50 mg bid
to gliclazide up to 320
mg daily as add-on
therapy in patients with
type 2 diabetes
11/14/2008 Diabetic A clinical study to A clinical trial controlled
inadequately of surgical 100 Not Applicable
evaluate effect of treatment
with metforminof Type2
surgery for control of Diabetes
monotherapy.in non
Type2 diabetes in morbidly obese
overweight individuals patients.
4/1/2009 Diabetic A clinical study to Open Label, Phase 3
compare effects and Randomized,
safety Of recombinant Multicentric Study To
Insulin Glargine Establish Safety And
manufactured by Biocon Efficacy Of Recombinant
Ltd Compared to Insulin Glargine
marketed Glargine Manufactured By Biocon
1/15/2009 Diabetic A clinical In
(Lantus) study to study
patients of A
LtdMulticenter,
Compared To
the
Typeeffects of the drug
1 Diabetes Randomized,
LantusTM In TypeDouble-
1
TZP-101
Mellitus. in patients Blind,
DiabetesPlacebo-
Mellitus
with severe Controlled,Dose-
Patients.
gastroparesis (delayed Ranging Study to
gastric emptying)due to Assess the Efficacy and
Diabetes Mellitus Safety of TZP-101 when
6/14/2010 Diabetic A clinical trial to study A Multicenter, Phase 3
Administered as a 30
the blood sugar Randomized, Double-
Minute I.V. Infusion to
lowering effects and Blind, Placebo Control
Subjects with Severe
safety of oral insulin Study of IN-105 tablets
Gastroparesis due to
(IN-105 tablets) in [oral insulin] in Patients
Diabetes Mellitus
patients of type 2 with Type 2 Diabetes
Diabetes Mellitus. Mellitus who have
1/29/2010 Diabetic To assess the anti- Extended
inadequate multicentric
Glycemic 600 Phase 3
diabetic effect of trial of Vijayasar
Control on Optimal
Vijayasar (extract of (Pterocarpus
doses of Extended
heartwood of - marsupium) in the
Release Metformin
Pterocarpus management
Tablets. of Type 2
marsupium) in the Diabetes Mellitus.
12/3/2009 Diabetic A clinical trial to study A Randomized, Open 10 Phase 2
management of two
the safety and label, Four Arms
groups of Type 2
effectiveness of a Parallel Study to
diabetes mellitus in
monoclonal antibody in Evaluate the Safety and
patients (1)who were
combination with Efficacy of anti-CD6
uncontrolled by
methotrexate in monoclonal antibody
12/3/2009 allopathic
A oral to study
clinicalwith
trial A Phase II Study to Phase 2
Diabetic patients
hypoglycemic
active
drugs. (2)
(T1h mAb) in
the safety and
rheumatoid efficacy
arthritis Evaluate
Combination With and
the Safety
controlled by
of a monoclonal allopathic Efficacy of anti-CD6
Methotrexate in Patients
oral hypoglycemic
antibody in patients drugs monoclonal antibody
With Active Rheumatoid
but
withopted
activefor Vijayasar.
psoriasis (T1h mAb) in Patients
Arthritis
with Active Psoriasis.
4/6/2010 Diabetic A clinical trial to study A triple blind, Phase 2
the effects of 2 herbal randomized, double
products as dietary dummy, prospective
supplements for Male placebo controlled dose
Sexual Health determination study to
investigate the safety
and efficacy of E-MA-H
and E-MA-HP capsules
as a dietary supplement
for Male Sexual Health.
4/15/2010 Diabetic A Study for Patients A 12-Week,Double- Phase 2
With Type 2 Diabetes Blind, Placebo-
Mellitus Controlled Trial of
LY2428757 in Patients
With Type 2 Diabetes
Mellitus
6/25/2010 Diabetic A Phase II clinical trial Safety and Efficacy of 300 Phase 2
to study the effects of TRC4186 in the
TRC4186, an treatment of stable
investigational new heart failure associated
drug in patients with with HbA1 ≥ 6.5% or
stable heart failure type 2 Diabetes
associated with type 2 receiving oral
diabetes mellitus hypoglycaemic therapy
receiving oral anti- (with or without
6/14/2010 Diabetic Effect of drug
diabetic insulin detemir
with or A 26 weekinsulin)
additional randomised,
as an 444 Phase 4
and insulin
without glargine on
insulin. multinational, open
add-on to conventional
blood glucose control in labelled,
treatment2 for
armed,
heart
subjects with type 2 parallel
failure. group, treat-to-
diabetes target once daily
treatment trial with
insulin detemir versus
7/27/2009 Diabetic "The effectiveness of a "The effectiveness
insulin glargine, both of a
in 86 Phase 2/Phase 3
behavioral change behavioral
combination change
with
communication model communication model
metformin in subjects
in promoting physical in promoting
with physical
type 2 diabetes
activity among females activity among females
with typeII Diabetes with typeII Diabetes
9/8/2009 Diabetic A clinical trial to study
mellitus"
EFFICACY AND SAFETY
mellitus"
Phase 3
the effects of OF TWO FIXED DOSES
Ralfinamide in patients (160 OR 320 MG/DAY)
with chronic OF RALFINAMIDE IN
neuropathic low back PATIENTS WITH
pain. CHRONIC
NEUROPATHIC LOW
10/6/2010 Diabetic A clinical trial to study BACK
A Randomized,
PAIN. A Active 274 Phase 3
safety and efficacy of MULTICENTER,
Controlled, Parallel
two drugs Insugen® R DOUBLE-BLIND,
Group, Multi-Center,
and Insugen® N with RANDOMISED,
Two Stage, Open Label,
Actrapid® and PLACEBO-CONTROLLED
Study Comparing
Insulatard® in Patients 12-WEEK
Safety andSTUDY WITH
with Type 1 Diabetes LONG-TERM
Immunogenicity of
Mellitus. EXTENSION.
Insugen® R and
30-04-2009 Diabetic A randomized double The effect of
Insugen® various
N with 100 Not Applicable
blind active controlled exercises
Actrapid®yogic/walking
and
parallel clinical trial to on serum insulin
Insulatard® level
in Patients
compare the effect of and
with glycemic control in
Type 1 Diabetes
exercises(yogic/walking patients
Mellitus with type 2
) on serum insulin level diabetes
19-06-2009 Diabetic Randomized, db, A Randomized, Double- Phase 3
and glycemic control in
Placebo-Controlled 18 Blind, Placebo-
patients with type 2
Week Study of BI 1356 Controlled Parallel
diabetes with high and
in Type 2 Diabetic Group Efficacy and
low serum insulin
Patients With Safety Study of BI 1356
values
Insufficient Glycaemic (5 mg Administered
Control on a Orally Once Daily) Over
4/8/2009 Diabetic Efficacy and Safety A Multicenter, Phase 3
Sulfonylurea Drug 18 Weeks in Type 2
Study of Alogliptin Randomized, Double-
Diabetic Patients With
Compared to Glipizide Blind Study to Evaluate
Insufficient Glycaemic
in Elderly Diabetics the Efficacy and Safety
Control (HbA1c 7.0-
of Alogliptin Compared
10%) Despite
to Glipizide in Elderly
Background Therapy
Subjects with Type 2
With a Sulfonylurea
Diabetes
Drug.
13-01-2010 Diabetic A clinical Trial to A phase III randomised, 792 Phase 3
compare the effects and double-blind, placebo-
safety of different controlled parallel group
combinations of the trial study to compare the
drug and metformin efficacy and safety of
over 24 weeks in drug twice daily
naïve or previously administration of the
treated (after with free combination of BI
10/9/2009 Diabetic A comparison
holding of various
the treatment A study
1356 2.5ofmg
comparative
+ Phase 4
antioxidant
for 4 weeks)preparations
type 2 effects
metforminof Antioxidants
500 mg, or
on insulin
diabetic sensitivity
patients within on Insulin
of BI 1356Sensitivity
2.5 mg + in
Type 2 diabetes
poor control of blood type 2 diabetes
metformin 1000 mg,
patients
sugar levels. mellitus: A Randomized
with the individual
Double Blinded
components Placebo-
26-05-2009 Diabetic A Research Study To A Phase 2a, of 72 Phase 2
Controlled
metformin Trial
(500 mg or
Assess The Randomized, Double
Effectiveness And 1000 mg, twice
Blind, Placebo- daily),
Safety Of Different and BI 1356Parallel
Controlled, (5.0 mg,
Doses Of Oral PF- once
Groupdaily)
Studyover 24
00489791 In The weeks in drugThe
Investigating naïve or
Dose-
Treatment Of Adult previously treated
Response Of PF- (4
Patients With weeks
00489791wash-out
On Acuteand 2
1/1/2007 A Study Evaluating weeks
A Phase placebo run-in)
II Prospective, Phase 2
Diabetic Pulmonary Arterial Hemodynamics
type 2 diabetic
In
patients
Efficacy And Safety Of
Hypertension. Randomized,
Subjects WithMulti-
Idiopathic
PF-04523655 Versus with insufficient
Center, Diabetic
And Familial Pulmonary
Laser In Subjects With glycaemic
Macular
ARTERIAL control
Edema Dose
Diabetic Macular Edema Ranging, Comparator
Hypertension.
(DEGAS) Study Evaluating the
15-04-2010 Diabetic A Comparison of Adding A Comparison
Efficacy of Adding
and Safety of 240 Phase 4
Exenatide With Exenatide
PF-04523655 WithVersus
Switching to Exenatide Switching to Exenatide
Laser Therapy (DEGAS)
in Patients With Type 2 in Patients With Type 2
Diabetes Experiencing Diabetes Experiencing
Inadequate Glycemic Inadequate Glycemic
24-03-2010 Diabetic Evaluate Efficacy and A 24-Week National, Phase 3
Control With Sitagliptin Control With Sitagliptin
Safety of Saxagliptin in Multi-centre,
Plus Metformin Plus Metformin
Adult Indian Patients Randomized, Parallel-
with Type 2 Diabetes group, Double-blind,
inadequate glycemic Placebo-controlled,
control. Phase IIIb study in
India to Evaluate the
30-06-2009 Diabetic Oral Insulin study for A Phase 2b, 120 Phase 2
Efficacy and Safety of
Type 2 Diabetes comparative, two arm
Saxagliptin in Adult
Mellitus randomized, placebo-
Patients with Type 2
controlled, double
Diabetes who have
blinded multi-centric
Inadequate Glycaemic
study to Evaluate the
Control with Diet and
10/5/2010 Infinnium-Core(TM) Safety, Tolerability, and
Infinnium-Core(TM) 150 Phase 4
Diabetic Exercise.
Registry: To Study the Registry:ofSafety
Efficacy Oral Insulin
and
Saftey and efficacy of 16 mg /day
Efficacy or placebo
of the
Infinnium-Core(TM) in subjects with Type 2
Infinnium-Core(TM)
Diabetes Mellitus (DM)
Coronary Stent for the Paclitaxel-Eluting
treatment of New who are currently
Coronary Stent Systemon
11/8/2009 Diabetic A Study to Compare the A Randomized,
diet alone Double-
or diet with 500 Phase 3
Coronary Artery for the Treatment of
Glycemic Effects, Blind, Parallel-Group,
monotherapy - novo
Blockage. Patients with De
Safety, and Tolerability Multicenter
Metformin Study
up to
to 2.5
Coronary Lesions
of Exenatide Once Compare
g/day the Glycemic
Weekly to Those of Effects, Safety, and
Sitagliptin and a Tolerability of Exenatide
Thiazolidinedione in Long-Acting
Subjects With Type 2 Release(Once Weekly)
Diabetes Treated With to Those of Sitagliptin
Metformin (DURATION - and a Thiazolidinedione
2) in Subjects With Type 2
Diabetes Mellitus
Treated With Metformin
6/1/2010 Diabetic A Study to Examine the A Comparator- 680 Phase 3
Effects of Exenatide Controlled Study to
Once-Weekly Injection Examine the Effects of
on Glucose Control and Exenatide Once-Weekly
Safety in Asian Subjects Injection on Glucose
Control (HbA1c) and
Safety in Asian Subjects
30-11-2009 Diabetic Safety and Efficacy of A Randomized,
With Double-
Type 2 Diabetes Phase 3
Albiglutide in Type 2 Blind, Placebo-
Mellitus Managed With
Diabetes Controlled, Parallel-
Oral Antidiabetic
Group, Multicenter
Medications
Study to Determine the
Efficacy and Safety of
Albiglutide When Used
in Combination With
14-07-2009 Diabetic Long-Term Safety An Open Label,
Pioglitazone WithMulti-
or 450 Phase 3
Study to Evaluate the Center,
Without Long-Term
Metformin in
Safety of Extension Study
Subjects with to 2
Type
Dutogliptin/PHX1149T Evaluate
Diabetes the Safety of
Mellitus.
in Subjects With Type 2 Dutogliptin / PHX1149T
Diabetes Mellitus in Subjects with Type 2
14-04-2010 Diabetic A clinical trial to To study the safety and 20 Phase 2/Phase 3
Diabetes Mellitus
evaluate the safety and efficacy of
efficacy of ReliDerm®DT in
ReliDerm®DT in patients with chronic
patients of non healing diabetic foot ulcer
diabetic foot ulcer
30-06-2010 Diabetic Effects of Naturlose Effects of Naturlose 550 Phase 3
(Tagatose) on blood (Tagatose) on blood
sugar Control and sugar Control and
Safety of Naturlose Safety of Naturlose
Over One Year in Over One Year in
Subjects with Type 2 Subjects with Type 2
7/8/2009 Diabetic Effect of Naturo fruit Evaluation of the effect 36 Phase 3
Diabetes under Diet Diabetes under Diet
bars in type-II diabetes of Naturo fruit bars in
Control and Exercise Control and Exercise
mellitus patients with type-II
diabetes mellitus
20-01-2010 Diabetic A clinical trial to study A multi-centric, 120 Phase 3

the safety and efficacy randomized, double
of 2mg and 4mg of blind study to evaluate
ZYH1 compared to the safety and efficacy
Pioglitazone 45mg in of 2mg and 4mg of
dyslipidemia with type 2 ZYH1 compared to
27-07-2009 Diabetic A clinical trial to A multi-center, double- 330 Phase 3
diabetes mellitus. Pioglitazone 45mg in
compare effect of masked study of the
dyslipidemia with type 2
Travoprost APS to safety and efficacy of
diabetes mellitus.
TRAVATAN in patients Travoprost APS
with open-angle compared to TRAVATAN
glaucoma or ocular in patients with open-
14-01-2010 Diabetic A clinical trial to study Efficacy of prophylactic Phase 2/Phase 3
hypertension angle glaucoma or
the effect of intravenous calcium
ocular hypertension.
prophylactic administration in first 5
intravenous calcium in days of life in high risk
preventing neonatal neonates to prevent
early onset early onset neonatal
26-05-2010 Diabetic Study with HO/03/03 in Safety and efficacy of 146 Phase 2
hypocalcemia. hypocalcemia
the treatment of Plantar HO/03/03 in the
Neuropathic Diabetic treatment of Planatar
Foot Ulcer. Neuropathic Diabetic
Foot Ulcers.
A 12-week multi-center,
randomized, double-
blind,
23-02-2010 Diabetic Efficacy and Safety of A Multicenter,
placebocontrolled, Phase 3
Alogiptin plus Metformin parallel-group
Randomized, Double- adaptive
Compared to Glipizide Blind,
designActivestudy? to
plus Metformin in Controlled
evaluate the Study to on
efficacy
Subjects with Type 2 Evaluate the Durability
blood glucose control
Diabetes Mellitus. of the
and Efficacy
safety and doses
of five
Safety of Alogliptin
of LCQ908 (2, 5, 10, 15
Compared
and 20 to Glipizide
mg) or
7/1/2010 Diabetic A 12 Week Study in When Used100
sitagliptin in mg on a Phase 2
Patients With Type 2 Combination with
background therapy of
Diabetes Mellitus Metformin
metformin in Subjects
in obese
(T2DM) with Type with
patients 2 Diabetes.
type 2
diabetes
4/9/2009 Diabetic Evaluation of Safety Evaluation of Safety 26 Phase 2
and Efficacy of Mersina, and Efficacy of Mersina,
an Ayurvedic an Ayurvedic
formulation: A double formulation: A double
blind, placebo blind, placebo
controlled study in type controlled study in type
22-01-2010 Diabetic Clinical trial to study Stem cell therapy- 20 Not Applicable
2 diabetic patients with 2 diabetic patients with
the safety and efficacy Cellular Cardio
Secondary failure to Secondary failure to
of stemcell therapy in myoplasty for patients
Oral drugs Oral drugs
patients with heart with heart diseases
diseases
2/12/2009 Diabetic A clinical trial to studyDose Ranging Effects of 1 Phase 2
the effects of Naturlose Three Low-doses of
(Tagatose) in patients Naturlose? (Tagatose)
with mild type 2 on Glycemic Control
Diabetes Mellitus under and Safety of
control with Diet and Naturlose? (Tagatose)
Exercise over a period Over Six Months in
12/11/2009 Diabetic Dose Finding, Safety
of 6 months Dose Finding,
Subjects Safety
with Mild Type Phase 2/Phase 3
and Efficacy of Monthly and EfficacyMellitus
2 Diabetes of Monthly
Subcutaneous Subcutaneous
Under Control with Diet
Canakinumab Canakinumab
and Exercise.
Administration in Administration for the
Metformin Monotherapy Treatment of
Treated Type 2 Diabetic Hyperglycemia in
Patients Metformin Monotherapy
Treated Type 2 Diabetic
Patients: a Randomized,
Double-Blind, Placebo-
31-08-2009 Diabetic Study of an Ayurvedic Evaluation
Controlled, of Safety
Multi-Center 26 Phase 2
Formulation Limit for Study
and Efficacy of Limit, an
safety and efficacy in Ayurvedic formulation:
type 2 diabetic patients A double blind, placebo
with oral drug failure controlled study in type
2 diabetic patients with
Secondary failure to
Oral drugs
Esti trial total Site 1 Site 2 Site 3 Site 4
duration Sites
Years
no
1 Shree Hari Diabetes
Foundation
4 Years 20 Poona Hospital & Christian Medical Madras Diabetic Topiwala National
Research Centre, College Research Medical College &
Foundation BYL Nair Hospital
2 Years 1 Dept of
Physiotherapy
Months 25 Lakshmi Hospital, Lakeshore Hospital Kerala Institute of M.V.Diabetes Care

Medical Sciences & diabetes
(KIMS) Research Centre
1 Years 2 Diacon Hospital Medisys Clinisearch

India PVT Ltd
12 Months 4 TNMC & BYL Nair Seth G.S. Medical Deccan College of Vydehi Institute of
Hospital, Mumbai College & KEM Medical Sciences & Medical Science and
Central, Mumbai Hospital, Parel, Allied Research Centre,
400 008 Mumbai 400 012 hospitals,Kanchanb 82, EPIP area,
hag Whitefield.
Santoshnagar,Hyder Bangalore-560006
abad-500058
12 Months 4 TNMC & BYL Nair Seth G.S. Medical Vydehi Institute of Deccan College of
Hospital, Mumbai College & KEM Medical Science and Medical Sciences &
Central, Mumbai Hospital, Parel, Research Centre, Allied
400 008 Mumbai 400 012 82, EPIP area, hospitals,Kanchanb
Whitefield. hag
Bangalore-560 00 Santoshnagar,Hyder
abad-500058
3 Years 1 MADHAV
DIABETES
CENTRE
4 Diabetes Thyroid Bhagwan Mahaveer Manipal Hospital Medilink Research
Research Institute Jain Hospital Centre
Pvt Ltd
3 Years 2 Dept. of Hepatology Dept. of

Gastroenterology
and HNU, AIIMS
Years 15 Aravind Eye Dr.R.P Center for Aravind Eye Aravind Eye
Hospital Ophthalmic Hospital Hospital
Sciences
12 Months 1 OPD, Department of

Endocrinology &
Metabolism, AIIMS,
New Delhi
5 Months 1 Sheikh Zayed

Federal
Postgraduate
Medical Institute
4 Years 1 Prashanth Hospital
Months 2 All India Institute of All India Institute of

Medical Sciences Medical Sciences
2 Years 17 Department of Nanjappa Hospital Fortis Escorts Southern Railway

Cardiology, St. Hospital HQ Hospital
Johns Medical
College & Hospital
Years 8 S. R. Kalla Memorial M.S. Ramaiah Christian Medical Nizam's Institute of
Gastro & general Memorial Hospital College, Medical Sciences
Hospital
3 Years 1 Bombay Hospital
Months 15 Samatvam St. Johns college Medwin Sterling

Endocrinology and hospital, Hospitals,Chirag Ali Hospital,Sterling
Centre,No:2 , First A Sarjapur Road, Lane,Hyderabad Hospital Road, Mem
Cross Bangalore. Nagar,Ahmedabad
Road,Maranhalli, JP
Nagar IInd Phase,
Bangalore
1 Amrita Institute of
Medical Sciences
and Research
Center, Amrita Lane,
Elamakkara PO,
Cochin, Kerala
Months 16 M.S. Ramaiah St.John's medical Diacon Hospital Mediheights

Memorial Hospital College and Hospital Healthcare Pvt Ltd
2 Years 4 S C B Medical Medical college madras medical All India Institute of

college Hospital college Medical Sciences
(AIIMS)
Months 10 Chanre Center For L T M Medical Institute of Post

Rheumatology & Rheumatic Diseases College & L T M G Graduate Medical
Immunology Centre Hospital Education &
& Research Research
(CRIC&R)
Months 9 M S Ramaiah Manipal Hospital Bowring Hospital PSG Hospital

Memorial Hospital
Years 6 Balaji Clinic, Main 169, Parvati gaon, Pungaliya Hospital, Sector 27 A/150,
Road, Devipada, Bhagirathi Medical opp veer savarkar Nigadi pradhikaran
Borivali (E) Foundation bhavan, Shivaji
Nagar
6 Lady Ratan Tata Bhagwan Hahavir Instride Research Dr. V Seshiah
Medical Research Jain Hospital Institute Diabetes Care and
Center Research Institute
2 Years 6 Spandan Heart Avanti Institute of CARE Hospital Shri Ram Cardiac
Institute and Cardiology Center
Research Center
26 2 Swamy Diabetes Jothydev Diabetes

Weeks Months Centre and Research
Centre
4 Months 1 Diabetic clinic

OP,Thiruvananthapu
ram medical college
Years 21 Sri Ramachandra Vijaya Health Nizams Institute of CARE hospital,

medical College, Centre, Chennai Medical Sceinces, Hyderabad
Chennai Hyderabad
24 Months 8 Postgraduate Belgaum Diabetes Department of Bangalore Diabetes

Institute of Medical Center,2nd Floor, Endocrinology,diabe Hospital, No 16/M
Education & Maruti tes and Thimmaiah Road,
Research,Sector 12, Galli,Belgaum 590 Metabolism Miller Tank Bed
Chandigarh 160 012 001 ,Christian Medical Area, Vasanthnagar,
College Hospital,
3 Months 1 Mittal Hospital
Months 8 M. S. Ramaiah Diabetes Thyroid Dr. V Seshiah Department of

Hospital Hormone Research Diabetes Care and Endocrinology,
Institute Research Institute - Bhagwan Mahaveer
Department of Jain Hospital
Endocrinology
Years 4 Belgaum Diabetes Bhagwan Mahavir Bharti Research IRL Research

Centre Jain Hospital Institute of Diabetes Centre
and Endocrinology
168-175 Days 19 Diacon Hospital Kasturba Hospital V Seshiah Diabetics Jnana Sanjeevani
Diabetes care & Care and Research Medical Center
Research Center Center
Months 1 Diabetes OPD

Sassoon Hospital
8 Months 3 Bankers Heart Department Of Department Of

Institute Cardiology, Sri Cardiology, MediCiti
Venkateswara Hospital,
Institute Of Medical
Sciences
Months 4 Eye Research Dr. Rajendra Prasad Vittala International L.V. Prasad Eye
Center & Retina Centre for Institute of Institute
Foundation Ophthalmic Ophthalmology
Sciences,All India
Sciences
6 Gujarat Endocrine Coimbatore Diabetes Thyroid S.R. Kalla Hospital
Center Diabetes Foundation Hormone Research
Institute
20 Months 13 Ruby Hall Clinic Diabetes Thyroid Bharti Hospital Bangalore Diabetes
Hormone Research Hospital
Institute Pvt. Ltd.
56 Days 3 Jnana sanjeevini samatvam : Endocrinology

diabetes center endocrinology Diabetes Centre
diabetes center
2 Years 9 Baroda Heart Government Medical Arneja Heart Bankers Heart

Institute & Research College & Super Institute, Nagpur Institute, Vadodara
Center, Vadodara Speciality Hospital,
Nagpur
3 Years 8 Chowpatty Medical Bhagwan Mahaveer Diabetes Thyroid King Edward

Centre Jain Hospital Hormone Research Memorial Hospital
Institute
14 Gujarat Endocrine Diabetes Thyroid Jawaharlal Nehru The Bangalore
Center Hormone Research Medical College Diabetes Hospital
Institute
Years 8 Gokula Metropolis Dande Diabetes and Bangalore Diabetes Madras Diabetes
Clinical Research Heart Care, Centre Research
Center, M. S. Foundation
Ramaiah Memorial
Hospital,
3 Years 10 Pitale's Clinic, CARE Hospitals Bhatia Hospital Shivam Clinic

Diabetes and
hormone centre
10 Months 7 Dande Diabetes & Pravara Institute of Dhanwantari Joshi Hospital,

Heart Care Centre Medical Sciences Hospita Maharashtra
Medical Society
3 Years 25 Suyash Hospital Pvt St. John's Medical Aware Global Pallakad diabetic
Ltd College Department hospital, Hyderabad Center
of Endocrinology
6 Months 1 Consultant
Physician &
Diabetologist
Months 13 Le Bonheur Pai Clinic & DHL Research Sudeep Diabetes

Endocrine & Diagnostic Centre Centre, Care Centre,
Diabetes Clinic
8 Months 5 Aravind Eye Aravind Eye National institute of Convest Jain clinic
Hospital Hospital Ophthalmology group of hospitals
Months 1 Department Of
Pediatrics,LLRM
Medical
College,Meerut(U.P)
,INDIA
15 Months 9 Jain Institute of Dr. V Seshiah Sir Ganga Ram S.K Diabetes &
Vascular Sciences, Diabetes Research Hospital, research Center
Institute
Years 10 Medwin Hospital Trichy Diabetic Diabetomics Research Health
Speciality Center Institute in Diabetes,
Endocrinology &
Metabolism
(RHIDEM)
Years 5 Fortis Flt Lt Rajan Jnana Sanjeevini Diabetes Thyroid INSTITUTE OF

Dhal Hospital Medical Center Hormone Research CLINICAL
Institute (DTHRI) ENDOCRINOLOGY
AND DIABETES
CARE UNIT
Months 1 Jyoti Clinical &

Pathological
Laboratory
6 Months 1 Frontier Lifeline

Pvt.Ltd
1 Months 10 Bangalore Diabetes Thyroid Diabetes Care and Krishna Diabetes

Endocrinology and Hormone Research Research Centre Clinic and
Diabetes Research Institute Pvt. Ltd. Educational
Years 12 Amrita Institute of Bangalore Diabetes Madras Diabetes Health and

Medical Sciences Hospital Research Research Centre
Foundation
3 Months 1 Jyoti Clinical &

Pathological
Laboratory
Site 5 Site 6 Site 7 Site 8 Site 9
Institute of Post M V Hospital for Medwin hospitals, Lotus Diagnostics All India Institute of
Graduate Medical Diabetes and Medical Sciences
Education & Diabetic Research
Research and Center
SSKM Hospital
Arthur Asirvatham Dr. V Seshiah Diabetes Care & Cuttack Diabetes Rama Krishna
Hospital Diabetes Care Research Centre, Research Mission Seva
Foundation, Prathisthan
Little Flower Aditya Jyot Eye Regional Institute Of Advance Eye Center Retina Foundation
Hospital Trust Hospital Ophthalmlogy
Post Graduate Mahatma Gandhi KEM Hospital & Life Worth Super Baby Memorial
Institute of Medical Institute of Medical Seth G.S Medical Speciality Hospital Hospital
Sciences Sciences College
Diabetes Thyroid Bharti Research Medilink Research All India Institute of
Hormone Research Institute of Diabetes Centre Diabetes &
Institute Pvt. Ltd. and Research Research
Belgaum Diabetes Bangalore Diabetes Mediheights Health Dr.V.Seshiah Endocrinology

Hospital,Ground Hospital,LNo Care Private Diabetes Care& Diabetes Centre,640
floor, 16/M,Thimmaiah Limited, Opp Ajanta Research First main First
Maruthigalli,Belgau Road,Vasanthnagar Pharma,Hindustan Institute,No.31 A, Stage
m Bangalore Naka, Kandivli West, Ormes Road, Indiranagar,Bangalo
Mumbai Kilpauk,Chennai re
DiabetOmics India. JSS Medical College Postgraduate Madras Diabetes Shri Ramachandra
Hospital Institute of Medical Research Medical College &
Education & Foundation Research Institute
Research
St. John's Medical Nizam's Institute of Krishna Institute of BYL Nair Charitable Shubhechha
College Hospital Medical Sciences Medical Sciences Hospital, Multispecialty
Hospital
Apollo Hospital SRMC Owaisi Hospital and Amrita Institute of Shubhechha

Research Centre Medical Sciences Multispeciality
Hospital
INSTRIDE, 6 Behind Hotel Vasco,

poonam Nasik Road
arcade,1170/11
revenue colony, J.M
Road Shivaji Nagar,
Cosmopolitan Associates in
Medical Care Center Clinical
Endocrinology
Education and
Research
Deenanath Amrita Institute of

Mangeshkar Medical Sciences
Hospital and
Research Centre
Owasis Hospital & J.S.S.hospital, St. John's Medical M.S.Ramaiah Kovai Medical
Research Center, Mysore College and Memorial Hospital, Centre and Hospital,
Hyderabad Hospital, Bangalore Bangalore Coimbatore
Diabetes Unit,KEM Department of Diabetomics India,6-

Hospital Research Endocrinology and 3-349/ 17B ,Hindi
Center,6th Floor Metabolism,Room # Nagar,Banjara hills
Banoo Coyaji 311, 3rd Floor PO,Hyderabad-
Bldg,Sardar ,AIIMS,New Delhi - 500034
Moodliar Road, 110029
Orange Diabetes K.G.N. Diabetes and Pitale Diabetes and Department of

Specialty Clinic Endocrine Centre Hormone Centre Endocrinology,
Jawaharlal Nehru
Medical College and
Hospital
B.P Poddar Hospital Bangalore Diabetes S.R Kalla Memorial Dande Diabetes & Diabetes Care &
and Medical Hospital Gastro and General Heart Care Centre, Research Centre,
Research Hospital
The Bangalore Bangalore

Diabetes Hospital Endocrinology and
Diabetes Research
Centre
Amrita Institute of Medisys Clinisearch Diabetes Care & Jnana Sanjeevini Lotus Diagnostic
Medical Sciences India Pvt Ltd. Research Institute Medical Center Centre
CHL Apollo Sri Ramakrishna CHL Apollo CHL Apollo CHL Apollo
Hospitals, Indore. Heart Foundation & Hospitals, Indore. Hospitals, Indore. Hospitals, Indore.
Research Centre,
Coimbatore
Bharti Research Bangalore Diabetes Mediheights Health Samatvam, Science

Institute of Diabetes Centre Care Pvt Ltd & Research for
and Endocrinology Human Welfare
(BRIDE), Bharti Trust
Hospital
King Edward VII Care Hospital M S Ramaiah Health and Banaras Hindu
Memorial Hospital Medical College Research Centre University
Hospital
Madras Diabetes Diabetes Care and KEM Hospital M.V. Hospital For
Research Research Centre Diabetes Pvt. Ltd.
Foundation
Endocare Clinic ACEER Diabetes Care and Medisys Clinisearch Bhagawan

Research Centre India Pvt. Ltd. Mahaveer Jain
(Bangalore Diabetes Hospital
centre)
Akshay Hospital Poona Hospital & J. N. Medical

Research Center College, KLE
Hospital & Research
Center
Department of D,Clinarch Sai Venketeshwara Diabetomics Padmasree

Medicine hospital Diagnostics
Standard Laboratory Aruna Diabetes Post-Graduate B.J. Medical College HCG Medisurge
and Polyclinic Centre Institute of Medical & Civil Hospital, Hospital
Education &
Research (PGIMER)
Shroff Eye Hospital
Karnataka Institute St. John's Medical MV Hospital for Patil Hospital Om shree Swami
of Diabetology College & Hospital Diabetes Pvt Ltd samarth hospital
Krishna Diabetes Bangalore Belgaum Diabetes Diabetes Care & Bangalore Diabetes
Clinic and Endocrinology and Centre Research Center Centre
Educational Diabetes Research
Research Centre Center (BEDRC)
GOVT MEDICAL
COLLEGE
Medisys Clinisearch Bharti Research Belgaum Diabetes Research Health Endocare Clinic
India Pvt. Ltd. Institute of Diabetes Centre Institute in Diabetes
and Endocrinology
Jnana Sanjeevini Nizam?s institute of Pitale Diabetes & Samatvam: S.R Kalla Memorial
Medical Center Medical Sciences Hormone centre Endocrinology Hospital
Diabetes Centre
M S Ramaiah St.Johns Medical Kasturba Medical Dr V Seshiah Amrita Institute of

Memorial Hospital College College Diabetes Care and Medical Sciences
Research Institute, and Research
Centre
Park Clinic Apollo Gleneagles Manipal Acunova Medilink Research P.D. Hinduja
Hospitals Ltd Clinical Research Basement National Hospital &
Centre (Manipal Research Center
Hospital)
Narayana Netralaya Vision Research L.V. Prasad Eye L.V. Prasad Eye Dr. Shroff?s Charity
Foundation Institute Institute Eye Hospital
Avanti Institute of Assam MEdocal P.S.G Hospital Dr. B.R. Patel Care Hospital
Cardiology Pvt.Ltd College & Hospital Hospital
Nizam's Institute of Mediciti Hospital, 5- KEM Diabetes Clinic and Apollo Hospitals
Medical Sciences, 9-22, Secretariat Hospital,Sardar Research International
Dept of Road,Hyderabad Moodliar Road,Pune Centre,Shreeniwas Limited, Ahm-1A,
Endocrinology and Opp Dhantoli Bhat GIDC Estate-
Metabolism, Park,Nagpur Ahmedabad
Punjagutta,Hyderab
ad
Dr V Seshiah Health and Gandhi Research BYL Nair Ch. JNANA

Diabetes Care and Research Center Institute Hospital SANJEEVINI
Research Institute MEDICAL CENTER
Sparsh Orthopaedic
Hospital
Brain and Mind Neuro Care Centre, Baby Memorial Mallikatta Neuro and Deenanath
Institute, Nagpur Lucknow Hospital, Calicut Research Centre, Mangeshkar
Mangalore Hospital and
Reserch center,
Pune
St. John Medical Deenanath Sunil's Diabetic Research Health Health and
College Hospital, Mangeshkar Care and Research Institute in Diabetes, Research Centre,
Hospital and Centre
Research Centre
K G Hospital Sterling Hospital Diabetes Unit 6TH Nizam's Institute of

Floor Medical Sciences
DIACARE IPGMER and SSKM Dr Vaishnavas Diabetes Care and Hormone Care and
Hospital Diabetes Clinic Research Centre Research Centre
Rudrawadi Hospital
Department of Trichy Diabetes Mediciti Hospital Global Hospitals Medwin Hospitals

Medicine Speciality Center (P)
Ltd
Bangalore St. John?s Medical Dia-care Clinic

Endocrinology and College & Hospital
Diabetes Centre
Bharti research
institute of Diabetes
and Endocrinology
Sunil's Diabetes
care and Research
Centre
Gokula Metropolis King George Diabetes Thyroid

Clinical Research Hospital Hormone Research
Centre Institute
KEM Hospital Mediciti Hospitals Care Hospital Nizams Institute of Osmania General
Medical Sciences Hospital
Orange Diabetes Prince Aly Khan Endocrine and All India Institute of Hormone Care
Speciality Clinic Hospital, Diabetes Centre Medical Sciences Centre
Shroff Eye Hospital
Shreenath Hospital Krishna Institute of

Medical Sciences
Ltd
Dept of Medicine,
JSS Medical College
Hospital ,Ramanuja
Road, Agrahara,
Mysore
Fortis Escorts
Hospital
Dayanand Medical Apollo Hospitals, Neurology Centre , Ruby General Pankaj Gupta Clinic,
college & hospital, Hyderabad Ahemdabad Hospital, Kolkata Jaipur
Ludhiana
Indraprastha Apollo Apollo Hospital, Apollo Speciality Diabetologist Krishna Diabetes
Hospital Hospital Spectra Research Clinic and
Clinical Centre, Educational
Research Centre,
Coimbatore Health and Department of Hubli Clinical ACEER
Diabetes Foundation Research Division Medicine research Center
Life care Institue of

Medical Sciences &
Research
Pushpawati Diabetes, Thyroid Mediciti Hospitals Medwin Hospitals Krishna Institute of

Singhania Research and Endocrine medical sciences
Institute Centre Ltd
Diacon Hospital and Moses Diabetes and Sunil's Diabetes Sunil's Diabetes
Research Centre Medical Center Care Research Care Research
Site 25
Mediheights
Healthcare Private
Limited

Ctri Data Base India Icmr

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Ctri Data Base India Icmr

Uploaded by

Copyright:

Available Formats

Clinical trial registry database India/WHO

S. Trial UTRN.WHO CTRI No.and Status of

1 Trial 1 TEMP UTRN CTRI/2008/091 Completed

2 Trial 2 TEMP UTRN CTRI/2010/091 Open to

3 Trial 3 TEMP UTRN CTRI/2008/091 Completed

4 Trial 4 TEMP UTRN CTRI/2009/091 Open to

5 Trial 5 TEMP UTRN CTRI/2009/091 Completed

6 Trial 6 TEMP UTRN CTRI/2009/091 Open to

7 Trial 7 TEMP UTRN CTRI/2010/091 Closed to

8 Trial 8 TEMP UTRN CTRI/2010/091 Completed

9 Trial 9 TEMP UTRN CTRI/2010/091 Closed to

11 Trial 11 TEMP UTRN CTRI/2009/091 Open to

12 Trial 12 TEMP UTRN CTRI/2008/091 Open to

13 Trial 13 TEMP UTRN CTRI/2009/091 Open to

14 Trial 14 TEMP UTRN CTRI/2009/091 Open to

15 Trial 15 TEMP UTRN CTRI/2009/091 Open to

16 Trial 16 TEMP UTRN CTRI/2009/091 Open to

17 Trial 17 TEMP UTRN CTRI/2010/091 Open to

18 Trial 18 TEMP UTRN CTRI/2007/091 Open to

19 Trial 19 TEMP UTRN CTRI/2008/091 Not yet

20 Trial 20 TEMP UTRN CTRI/2010/091 Open to

22 Trial 22 TEMP UTRN CTRI/2010/091 Not yet

Last Verified Last Updated Speciality-

5/27/2009 4/8/2010 Congestive heart

acute renal failure

3/9/2009 4/23/2009 Chronic

5/13/2009 3/18/2010 Chronic

6/18/2009 6/24/2010 Septic Shock

2/1/2010 2/1/2010 H1N1

1/15/2010 4/19/2010 H1N1

1/1/2007 5/13/2010 H1N1

5/11/2010 5/5/2010 Shock

2/11/2009 2/11/2009 cardiac

5/13/2009 5/15/2009 Pulmonary Arterial

1/1/2007 5/13/2009 Pulmonary Arterial

5/13/2009 4/27/2009 Pulmonary Arterial

5/27/2009 5/26/2009 Pulmonary Arterial

4/30/2010 6/14/2010 Pulmonary Arterial

4/28/2008 5/20/2010 life-threatening

4/30/2008 1/1/2007 life-threatening

1/1/2007 7/9/2010 life-threatening

7/13/2010 7/13/2010 life-threatening

Cardiac rehabilitation and quality The effects of exercise based cardiac 28

A clinical trial to study the effects A Phase III, Multicenter, Open-Label 31

Not 1 Years 1 Department

Phase 4 Months 1 Government

Christia Orchid Shatabd Deenant Chatrap Oyster Mahavi S.M.S

S. Trial UTRN.WHO CTRI Status Last Last

Nephro OPTIMIZATION OF PLASMA LEVEL MONITORING 25 Phase 4

Nephro "The effectiveness of a "The effectiveness of a 86 Phase

Nephro Comparison of efficacy of Comparison of efficacy of 50 Not

Nephro Research Study to A Phase III, Randomized, 350 Phase 3

17 Mont 10 Pushpaw S.K. Soni MAMC Deenanat P. D. Apex Krishna

Departme Muljibhai Departme

S. no Trial No. UTRN.WHO CTRI No.and Date Status of TrialWHO

1 Trial 1 TEMP UTRN CTRI/2007/091/0000 Closed to

3 Trial 3 TEMP UTRN CTRI/2008/091/0000 Open to recruitment

4 Trial 4 TEMP UTRN CTRI/2008/091/0000 Open to recruitment

5 Trial 5 TEMP UTRN CTRI/2008/091/0000 Closed to

6 Trial 6 TEMP UTRN CTRI/2008/091/0000 Completed

7 Trial 7 TEMP UTRN CTRI/2008/091/0000 Closed to

8 Trial 8 TEMP UTRN CTRI/2008/091/0000 Open to recruitment

9 Trial 9 TEMP UTRN CTRI/2008/091/0001 Completed

11 Trial 11 TEMP UTRN CTRI/2009/091/0001 Open to recruitment